id,InchiKey,Mol_name (IUPAC),IUPAC,Smiles,Pubchem_ID,CHEMBL_ID,Database,Assay,Phenotypic Assay ,Observation,Target,Receptor source/Animal Model,IC50,EC50,PEC50,DOI,Activity
SD_001,GKQPCPXONLDCMU-CCEZHUSRSA-N,Lacidipine,"diethyl-2,6-dimethyl-4-[2-[(E)-3-[(2-methylpropan-2-yl)oxy]-3-oxoprop-1-enyl]phenyl]-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2/C=C/C(=O)OC(C)(C)C)C(=O)OCC)C)C,5311217.0,CHEMBL460291,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_002,BIGYBMJQLJLKQS-CCEZHUSRSA-N,1,"(E)-N-(tert-butyl)-3-(2-(3,5-diethyl-2,6-dimethyl-1,4-dihydropyridin-4-yl)phenyl)acrylamide",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(NC(C)(C)C)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_003,CSJIXXKTZGEQLZ-BUHFOSPRSA-N,2,"diethyl (E)-4-(2-(3-(isobutylamino)-3-oxoprop-1-en-1-yl)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(NCC(C)C)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_004,MEKLNZVLWRNINM-FOCLMDBBSA-N,3,"diethyl (E)-4-(2-(3-(diethylamino)-3-oxoprop-1-en-1-yl)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(N(CC)CC)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_005,RHLCYONVROIQCW-FOCLMDBBSA-N,4,"diethyl (E)-4-(2-(3-(butyl(methyl)amino)-3-oxoprop-1-en-1-yl)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(N(C)CCCC)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_006,LOCJINCZWHKPOM-FOCLMDBBSA-N,5,"diethyl (E)-4-(2-(3-(tert-butyl(methyl)amino)-3-oxoprop-1-en-1-yl)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(N(C)C(C)(C)C)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_007,QVIWGIWGTFQTAZ-FMQUCBEESA-N,6,"diethyl (E)-4-(2-(3-(dipentylamino)-3-oxoprop-1-en-1-yl)phenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate",CCOC(C1=C(NC(C)=C(C(OCC)=O)C1C2=CC=CC=C2/C=C/C(N(CCCCC)CCCCC)=O)C)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,Systolic blood pressure,spontaneously hypertensive rats,,,,10.1007/s00044-011-9680-7,Active
SD_008,YSPAKWMWSFPXDS-AWEZNQCLSA-N,4i,(S)-Methyl 2-(2-butyl-4-chloro-1-methyl-1H-imidazole-5- carboxamido)-3-phenylpropanoate,O=C(OC)[C@@H](NC(C1=C(Cl)N=C(CCCC)N1C)=O)CC2=CC=CC=C2,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,HEK 293 and A549 cell lines,,,,10.1016/j.bmc.2015.04.024,Active
SD_009,DTAMTFWHWXFPBF-INIZCTEOSA-N,4k,(S)-Methyl 2-(2-butyl-4-chloro-1-methyl-1H-imidazole5-carboxamido)-3-(1H-indol-2-yl)propanoate,O=C(OC)[C@@H](NC(C1=C(Cl)N=C(CCCC)N1C)=O)CC(N2)=CC3=C2C=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,HEK 293 and A549 cell lines,,,,10.1016/j.bmc.2015.04.024,Active
SD_010,GTCDDBZIEKAAGW-ONGXEEELSA-N,5e,"(2S,3S)-2-(2-Butyl-4-chloro-1-methyl-1H-imidazole-5- carboxamido)-3-methylpentanoic acid",CC[C@H](C)[C@H](NC(C1=C(Cl)N=C(CCCC)N1C)=O)C(O)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,HEK 293 and A549 cell lines,,,,10.1016/j.bmc.2015.04.024,Active
SD_011,FKINCRVYAPJWGX-VIFPVBQESA-N,5h,(S)-2-(2-Butyl-4-chloro-1-methyl-1H-imidazole-5- carboxamido)-4-(methylthio) butanoic acid,O=C(O)[C@@H](NC(C1=C(Cl)N=C(CCCC)N1C)=O)CCSC,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,HEK 293 and A549 cell lines,,,,10.1016/j.bmc.2015.04.024,Active
SD_012,OUUUZZUBFNSEHN-ZDUSSCGKSA-N,5i,(S)-2-(2-Butyl-4-chloro-1-methyl-1H-imidazole-5- carboxamido)-3-phenylpropanoic acid (,O=C(O)[C@@H](NC(C1=C(Cl)N=C(CCCC)N1C)=O)CC2=CC=CC=C2,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,HEK 293 and A549 cell lines,,,,10.1016/j.bmc.2015.04.024,Active
SD_013,JSDRRTOADPPCHY-HSQYWUDLSA-N,Quinapril,"(3S)-2-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4-dihydro-1H-isoquinoline-3-carboxylic acid",CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CC3=CC=CC=C3C[C@H]2C(=O)O,54892.0,,ChEMBL,In vitro calcium channel blocking assays,,,,,,,,,Active
SD_014,GTCDDBZIEKAAGW-ONGXEEELSA-N,Diacid,"(2S,3S)-2-(2-Butyl-4-chloro-1-methyl-1H-imidazole-5- carboxamido)-3-methylpentanoic acid",O=C(O)[C@@H]1CC2=CC=CC=C2CN1C([C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,,,,,,,Active
SD_015,FWVLEESNKAYWAD-IEZWGBDMSA-N,5a,"(S)-5-(tert-butyl)-3-(((S)-1-oxo-4-phenyl-1-propoxybutan-2-yl)-L-alanyl)-2,3-dihydro-1,3,4-thiadiazole-2-carboxylic acid",OC([C@H]1N(N=C(C(C)(C)C)S1)C([C@H](C)N[C@H](C(OCCC)=O)CCC2=CC=CC=C2)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rats,,,,10.1021/jm00105a066,Active
SD_016,APWZQGVRPRWXQK-NOLJZWGESA-N,5b,"(S)-5-(tert-butyl)-3-(((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-2,3-dihydro-1,3,4-thiadiazole-2-carboxylic acid",OC([C@H]1N(N=C(C(C)(C)C)S1)C([C@H](C)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rats,,,,10.1021/jm00105a066,Active
SD_017,YCAMNSDXCCDILU-UHFFFAOYSA-N,4a,"N,2,2-trimethyl-6-nitro-2H-chromene-4-carbothioamide",CC1(C)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.87+0.05,10.1016/s0960-894x(01)80835-0,Active
SD_018,PHIPFVKBKRVXLC-UHFFFAOYSA-N,5a,"N,2,2-trimethyl-6-nitro-2H-chromene-4-carboxamide",CC1(C)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=O)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,7.97i-0.04,10.1016/s0960-894x(01)80835-0,Active
SD_019,JCVGBCGTJFOARS-UHFFFAOYSA-N,6a,"N-(2-cyanoethyl)-2,2-dimethyl-6-nitro-2H-chromene-4-carbothioamide",CC1(C)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.43_+0.28,10.1016/s0960-894x(01)80835-0,Active
SD_020,VCPZPWNACQTGGO-UHFFFAOYSA-N,7a,"N-(2-cyanoethyl)-2,2-dimethyl-6-nitro-2H-chromene-4-carboxamide",CC1(C)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=O)=C1.O,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.55-+0.11,10.1016/s0960-894x(01)80835-0,Active
SD_021,BXDAMADLNUAOGU-UHFFFAOYSA-N,4b,"2-(fluoromethyl)-N,2-dimethyl-6-nitro-2H-chromene-4-carbothioamide",CC1(CF)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.79+-0.36,10.1016/s0960-894x(01)80835-0,Active
SD_022,AILGDUYPTZPKMC-UHFFFAOYSA-N,5b,"2-(fluoromethyl)-N,2-dimethyl-6-nitro-2H-chromene-4-carboxamide",CC1(CF)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=O)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.05+-0.10,10.1016/s0960-894x(01)80835-0,Active
SD_023,DRQYNLODWXEJBU-UHFFFAOYSA-N,6b,N-(2-cyanoethyl)-2-(fluoromethyl)-2-methyl-6-nitro-2H-chromene-4-carbothioamide,CC1(CF)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.73-+0.04,10.1016/s0960-894x(01)80835-0,Active
SD_024,BQDKJLPXNCMOPC-UHFFFAOYSA-N,7b,N-(2-cyanoethyl)-2-(fluoromethyl)-2-methyl-6-nitro-2H-chromene-4-carboxamide,CC1(CF)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=O)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.40:k0.04,10.1016/s0960-894x(01)80835-0,Active
SD_025,YHZOAJUGGHFNBD-UHFFFAOYSA-N,4c,"2,2-bis(fluoromethyl)-N-methyl-6-nitro-2H-chromene-4-carbothioamide",S=C(NC)C1=CC(CF)(CF)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.32:+-0.11,10.1016/s0960-894x(01)80835-0,Active
SD_026,RVIQVZZLBZXTPU-UHFFFAOYSA-N,5c,"2,2-bis(fluoromethyl)-N-methyl-6-nitro-2H-chromene-4-carboxamide",O=C(NC)C1=CC(CF)(CF)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.29+-0.03,10.1016/s0960-894x(01)80835-0,Active
SD_027,LKUDLWNQCZSCQW-UHFFFAOYSA-N,6c,"N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitro-2H-chromene-4-carbothioamide",S=C(NCCC#N)C1=CC(CF)(CF)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.85+-0.24,10.1016/s0960-894x(01)80835-0,Active
SD_028,WMVNZVFRFPHGMS-UHFFFAOYSA-N,7c,"N-(2-cyanoethyl)-2,2-bis(fluoromethyl)-6-nitro-2H-chromene-4-carboxamide",O=C(NCCC#N)C1=CC(CF)(CF)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.65:t:0.03,10.1016/s0960-894x(01)80835-0,Active
SD_029,AJAFLLUYJOKNMU-UHFFFAOYSA-N,4d,"N,2-dimethyl-6-nitro-2-(trifluoromethyl)-2H-chromene-4-carbothioamide",CC1(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.52+-0.34,10.1016/s0960-894x(01)80835-0,Active
SD_030,ZUCNOWGRNYYKIC-UHFFFAOYSA-N,5d,"N,2-dimethyl-6-nitro-2-(trifluoromethyl)-2H-chromene-4-carboxamide",CC1(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C2C(C(NC)=O)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.57-+0.08,10.1016/s0960-894x(01)80835-0,Active
SD_031,SQOSTQAIAPBACI-UHFFFAOYSA-N,6d,N-(2-cyanoethyl)-2-methyl-6-nitro-2-(trifluoromethyl)-2H-chromene-4-carbothioamide,CC1(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=S)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.44-+0. I 1,10.1016/s0960-894x(01)80835-0,Active
SD_032,RZXASFQQAIJKSP-UHFFFAOYSA-N,7d,N-(2-cyanoethyl)-2-methyl-6-nitro-2-(trifluoromethyl)-2H-chromene-4-carboxamide,CC1(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C2C(C(NCCC#N)=O)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.16-+-0.02,10.1016/s0960-894x(01)80835-0,Active
SD_033,YCENYDJESABRIW-UHFFFAOYSA-N,4e,"N-methyl-6-nitro-2,2-bis(trifluoromethyl)-2H-chromene-4-carbothioamide",S=C(NC)C1=CC(C(F)(F)F)(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.20+-0.02,10.1016/s0960-894x(01)80835-0,Active
SD_034,OELSKZONJFAGSZ-UHFFFAOYSA-N,5e,"N-methyl-6-nitro-2,2-bis(trifluoromethyl)-2H-chromene-4-carboxamide",O=C(NC)C1=CC(C(F)(F)F)(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,8.83+-0.09,10.1016/s0960-894x(01)80835-0,Active
SD_035,VAVKORLWGHXGMK-UHFFFAOYSA-N,6e,"N-(2-cyanoethyl)-6-nitro-2,2-bis(trifluoromethyl)-2H-chromene-4-carbothioamide",S=C(NCCC#N)C1=CC(C(F)(F)F)(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.36-+0.13,10.1016/s0960-894x(01)80835-0,Active
SD_036,OLSAXZAKGACYRU-UHFFFAOYSA-N,7e,"N-(2-cyanoethyl)-6-nitro-2,2-bis(trifluoromethyl)-2H-chromene-4-carboxamide",O=C(NCCC#N)C1=CC(C(F)(F)F)(C(F)(F)F)OC2=CC=C([N+]([O-])=O)C=C21,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.31_+0.03,10.1016/s0960-894x(01)80835-0,Active
SD_037,TVZCRIROJQEVOT-UHFFFAOYSA-N,cromakalim,"(3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxopyrrolidin-1-yl)chromane-6-carbonitrile",N#CC1=CC([C@H]([C@@H2]CO2)N3CCCC3)=C2C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,9.31-+0.03,10.1016/s0960-894x(01)80835-0,Active
SD_038,IVVNZDGDKPTYHK-UHFFFAOYSA-N,pinacidil,"(E)-2-cyano-1-(3,3-dimethylbutan-2-yl)-3-(pyridin-4-yl)guanidine",CC(N/C(NC1=CC=NC=C1)=N\C#N)C(C)(C)C,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,6.14+-0.03,10.1016/s0960-894x(01)80835-0,Active
SD_039,GKEMHVLBZNVZOI-MTATWXBHSA-N,RP49356,(2R)-N-methyl-2-(pyridin-3-yl)tetrahydro-2H-thiopyran-2-carbothioamide 1-oxide,O=S1[C@](C2=CC=CN=C2)(C(NC)=S)CCCC1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Vasorelaxation,K + channel openers,rat isolated aorta,,,6.28a_+0.04,10.1016/s0960-894x(01)80835-0,Active
SD_040,LGGFATBGHIJSPG-UHFFFAOYSA-N,1a,"2-(4-((2-ethyl-6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-benzo[d]imidazol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(N=C4CC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0103 ± 0.0016,,,10.1021/acsmedchemlett.8b00335,Active
SD_041,JFKWXCTYQRHRFE-UHFFFAOYSA-N,1b,"2-(4-((6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(N=C4CCC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.004 ± 0.0005,,,10.1021/acsmedchemlett.8b00335,Active
SD_042,FXBDUXYXSCLWSG-UHFFFAOYSA-N,1c,"2-(4-((2-butyl-6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-benzo[d]imidazol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(N=C4CCCC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0099 ± 0.0009,,,10.1021/acsmedchemlett.8b00335,Active
SD_043,POORHZOIEARQQY-UHFFFAOYSA-N,1d,"2-(4-((2-ethyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-benzo[d]imidazol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(N=C4CC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0121 ± 0.0003,,,10.1021/acsmedchemlett.8b00335,Active
SD_044,FNSGSFGLTWLQNZ-UHFFFAOYSA-N,1e,"2-(4-((6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0053 ± 0.0011,,,10.1021/acsmedchemlett.8b00335,Active
SD_045,MTZXOTRUDRHIGY-UHFFFAOYSA-N,1f,"2-(4-((2-butyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0105 ± 0.0018,,,10.1021/acsmedchemlett.8b00335,Active
SD_046,KGMOEMPOXSCFAL-UHFFFAOYSA-N,2a,"2-(4-((2-ethyl-6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.012 ± 0.0017,,,10.1021/acsmedchemlett.8b00335,Active
SD_047,LEHYQRFZBPWEEF-UHFFFAOYSA-N,2b,"2-(4-((6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0044 ± 0.0002,,,10.1021/acsmedchemlett.8b00335,Active
SD_048,BILXJAQIWNOYFA-UHFFFAOYSA-N,2c,"2-(4-((2-butyl-6-(4-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCCC)C=CC(C6OC7=C(N6)C(C)=CC=C7)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0107 ± 0.0023,,,10.1021/acsmedchemlett.8b00335,Active
SD_049,PSDLULDHHNCXEG-UHFFFAOYSA-N,2d,"2-(4-((2-ethyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0136 ± 0.0015,,,10.1021/acsmedchemlett.8b00335,Active
SD_050,FNSGSFGLTWLQNZ-UHFFFAOYSA-N,2e,"2-(4-((6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-2-propyl-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0056 ± 0.0008,,,10.1021/acsmedchemlett.8b00335,Active
SD_051,MTZXOTRUDRHIGY-UHFFFAOYSA-N,2f,"2-(4-((2-butyl-6-(7-methyl-2,3-dihydrobenzo[d]oxazol-2-yl)-1H-indol-1-yl)methyl)indolin-1-yl)benzoic acid",O=C(O)C1=CC=CC=C1N2C3=C(CC2)C(CN4C5=C(C=C4CCCC)C=CC(C6OC7=C(N6)C=CC=C7C)=C5)=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0097 ± 0.0009,,,10.1021/acsmedchemlett.8b00335,Active
SD_052,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,spontaneously hypertensive rats,0.0146 ± 0.0016,,,10.1021/acsmedchemlett.8b00335,Active
SD_053,AIUQSSQFNDHINZ-UHFFFAOYSA-N,7a,"3-Benzyl-3H-[1,2,4]triazolo[5,1-b]quinazolin-9-one",O=C1N(N=CN2CC3=CC=CC=C3)C2=NC4=C1C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_054,UWPLBLQZSBVZCJ-UHFFFAOYSA-N,7b,"3-Benzyl-2-methyl-3H-[1,2,4]triazolo[5,1-b]quinazolin-9-one",O=C1N(N=C(C)N2CC3=CC=CC=C3)C2=NC4=C1C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_055,MWBCSBYKMKINDS-UHFFFAOYSA-N,7c,"3-Benzyl-2-propyl-3H-[1,2,4]triazolo[5,1-b]quinazolin-9-one",O=C1N(N=C(CCC)N2CC3=CC=CC=C3)C2=NC4=C1C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_056,AEUOIDZLAYAUPK-UHFFFAOYSA-N,7d,"3-Benzyl-2-chloromethyl-3H-[1,2,4]triazolo[5,1-b]quinazolin-9-one",O=C1N(N=C(CCl)N2CC3=CC=CC=C3)C2=NC4=C1C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_057,VSUVGFRJFNDJCQ-KPFQTZNGSA-N,7e,"3-benzyl-2-(morphinyl methyl)-3h-[1,2,4]triazolo[5,1-b] quinazolin-9-one",O=C1N(N=C(COC2=C3O[C@@H]4[C@]56C3=C(C=C2)C[C@@H](N(CC6)C)[C@]5([H])C=C[C@@H]4O)N7CC8=CC=CC=C8)C7=NC9=C1C=CC=C9,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_058,NFONOOHXEVRGDY-UHFFFAOYSA-N,7f,"3-Benzyl-2-(piperidyl methyl)-3H-[1,2,4]triazolo[5,1-b] quinazolin-9-one",O=C1N(N=C(CN2CCCCC2)N3CC4=CC=CC=C4)C3=NC5=C1C=CC=C5,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_059,LOPFEZQKOKKSPU-UHFFFAOYSA-N,7g,"3-Benzyl-2-phenyl-3H-[1,2,4]triazolo[5,1-b]quinazolin-9-one",O=C1N(N=C(C2=CC=CC=C2)N3CC4=CC=CC=C4)C3=NC5=C1C=CC=C5,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_060,ZSYNPALAAFLLHN-UHFFFAOYSA-N,7h,"3-Benzyl-2-(4-methylphenyl)-3H-[1,2,4]triazolo[5,1- b]quinazolin-9-one",O=C1N(N=C(C2=CC=C(C)C=C2)N3CC4=CC=CC=C4)C3=NC5=C1C=CC=C5,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_061,YJGRJQAZHRMZGG-UHFFFAOYSA-N,7i,"3-Benzyl-2-(4-methoxyphenyl)-3H-[1,2,4]triazolo[5,1-b] quinazolin-9-one",O=C1N(N=C(C2=CC=C(OC)C=C2)N3CC4=CC=CC=C4)C3=NC5=C1C=CC=C5,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_062,SQQAGDTUMHHFBW-UHFFFAOYSA-N,7j,"3-benzyl-2-(4-ethoxyphenyl)-[1,2,4]triazolo[5,1-b]quinazolin-9(3H)-one",O=C1N(N=C(C2=CC=C(OCC)C=C2)N3CC4=CC=CC=C4)C3=NC5=C1C=CC=C5,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_063,IENZQIKPVFGBNW-UHFFFAOYSA-N,Prazocin,"[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(furan-2-yl)methanone",COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,decrease in systolic and/or diastolic blood pressure,,spontaneously hypertensive rats,,,,10.1016/j.bmc.2007.03.007,Active
SD_064,KBTIIJJXAKTFCW-UHFFFAOYSA-N,V,1-(3-Mercapto-2-methylpropanoyl)-2-(4-methoxybenzyl)pyrrolidin-3-one,O=C1C(CC2=CC=C(OC)C=C2)N(C(C(C)CS)=O)CC1,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active
SD_065,MLDDNCAPYNCRSS-UHFFFAOYSA-N,VIa,1-(3-(Hydroxyimino)-2-(4-methoxybenzyl)pyrrolidin-1-yl)-3-mercapto-2-methyl propan-1-one,O=C(N1C(CC2=CC=C(OC)C=C2)C(CC1)=NO)C(C)CS,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active
SD_066,ROPWLEVZIMKXLG-UHFFFAOYSA-N,VIb,1-(3-(2-Hydroxyethylimino)-2-(4-methoxybenzyl)pyrrolidin-1-yl)-3-mercapto-2-methylpropan-1-one,O=C(N1C(CC2=CC=C(OC)C=C2)C(CC1)=NCCO)C(C)CS,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active
SD_067,PZWHURODFYXCPJ-UHFFFAOYSA-N,VIe,Ethyl-2-(1-(3-mercapto-2-methylpropanoyl)-2-(4-methoxybenzyl)pyrrolidin-3-ylidene amino)propanoate,CC(N=C1C(CC2=CC=C(OC)C=C2)N(C(C(C)CS)=O)CC1)C(OCC)=O,,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active
SD_068,FAKRSMQSSFJEIM-RQJHMYQMSA-N,Captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,,,ACE,,,,,10.1016/j.bmc.2009.03.008,Active
SD_069,USTBLMSPAVZZOE-UHFFFAOYSA-N,1,2-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazole,FC(C1=CC=C(NC(C2=CC=CC=C2)=N3)C3=C1)(F)F,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,467.75 ± 73.6,,10.1016/j.bmc.2010.04.027,Active
SD_070,TYIMNAOTGCKCIL-UHFFFAOYSA-N,2,2-(2-methoxyphenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole,COC(C=CC=C1)=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,574.85 ± 30.3,,10.1016/j.bmc.2010.04.027,Active
SD_071,VYCKDPYMYUPJHY-UHFFFAOYSA-N,3,2-(2-ethoxyphenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole,CCOC(C=CC=C1)=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,548.51 ± 77.1,,10.1016/j.bmc.2010.04.027,Active
SD_072,MPCBBVYRVHFPDL-UHFFFAOYSA-N,4,2-(o-tolyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole,FC(C1=CC=C(NC(C2=C([N+]([O-])=O)C=CC=C2)=N3)C3=C1)(F)F,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,15.03 ± 7.59,,10.1016/j.bmc.2010.04.027,Active
SD_073,NXVOCXHGCVHFSN-UHFFFAOYSA-N,5,4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)phenol,OC(C=C1)=CC=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,219.20 ± 71.6,,10.1016/j.bmc.2010.04.027,Active
SD_074,NBSDEXMSGCATJD-UHFFFAOYSA-N,6,2-(4-propoxyphenyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole,CCCOC(C=C1)=CC=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,524.49 ± 19.3,,10.1016/j.bmc.2010.04.027,Active
SD_075,XMYLWCQNUYURSL-UHFFFAOYSA-N,7,"N,N-dimethyl-4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)aniline",CN(C)C(C=C1)=CC=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,550.27 ± 84.5,,10.1016/j.bmc.2010.04.027,Active
SD_076,LLYOFESDMYBKIT-UHFFFAOYSA-N,8,2-methoxy-4-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)phenol,OC(C=C1)=C(OC)C=C1C2=NC3=CC(C(F)(F)F)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,140.14 ± 63.2,,10.1016/j.bmc.2010.04.027,Active
SD_077,JJGWOEAFWXCWAW-UHFFFAOYSA-N,9,"2-(Benzo[d][1,3]dioxol-5-yl)-5-(trifluoro methyl)-1H-benzo[d]imidazole",FC(C1=CC=C2NC(C3=CC=C(OCO4)C4=C3)=NC2=C1)(F)F,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,77.42 ± 9.41,,10.1016/j.bmc.2010.04.027,Active
SD_078,FHOXCSDDMCCTPM-UHFFFAOYSA-N,10,5-nitro-2-phenyl-1H-benzo[d]imidazole,O=[N+](C1=CC=C(NC(C2=CC=CC=C2)=N3)C3=C1)[O-],,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,35.1 ± 5.21,,10.1016/j.bmc.2010.04.027,Active
SD_079,ALBGTLCEMRDPLW-UHFFFAOYSA-N,11,2-(2-methoxyphenyl)-5-nitro-1H-benzo[d]imidazole,COC(C=CC=C1)=C1C2=NC3=CC([N+]([O-])=O)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,15.0 ± 1.12,,10.1016/j.bmc.2010.04.027,Active
SD_080,DUDFTECOBVTCRG-UHFFFAOYSA-N,12,2-(2-ethoxyphenyl)-5-nitro-1H-benzo[d]imidazole,CCOC(C=CC=C1)=C1C2=NC3=CC([N+]([O-])=O)=CC=C3N2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,14.12 ± 1.05,,10.1016/j.bmc.2010.04.027,Active
SD_081,LSNPOGOZVAHETR-UHFFFAOYSA-N,13,2-methoxy-4-(5-nitro-1H-benzo[d]imidazol-2-yl)phenol,COC1=C(O)C=CC(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,19.49 ± 1.79,,10.1016/j.bmc.2010.04.027,Active
SD_082,IAAMQNUXRWPNND-UHFFFAOYSA-N,14,"2-(3,4-dimethoxyphenyl)-5-nitro-1H-benzo[d]imidazole",COC1=C(OC)C=CC(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,301.9 ± 10.2,,10.1016/j.bmc.2010.04.027,Active
SD_083,IRXXSDFWKUMWQA-UHFFFAOYSA-N,15,"5-nitro-2-(2,3,4-trimethoxyphenyl)-1H-benzo[d]imidazole",COC1=C(OC)C=CC(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)=C1OC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,Vascular smooth muscle,rat aorta rings pre-contracted with noradrenaline and spontaneously hypertensive rats,,43.65 ± 2.37,,10.1016/j.bmc.2010.04.027,Active
SD_084,NEVKLLSLBHGCCW-NRFANRHFSA-N,1a,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)pentanoic acid",O=C(CCCC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,9.82 ± 4.20,,,https://doi.org/10.1016/j.bmc.2012.02.003,Active
SD_085,CLRQDBVTVSLGOD-IBGZPJMESA-N,1b,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)butanoic acid",O=C(CCC)N([C@@H](CC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,0.49 ± 0.10,,,10.1016/j.bmc.2012.02.003,Active
SD_086,FXELTRKWYHPHAE-IBGZPJMESA-N,1c,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)propionamido)pentanoic acid",O=C(CC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,1.60 ± 0.09,,,10.1016/j.bmc.2012.02.003,Active
SD_087,KSFHDWRRMJLZGV-QFIPXVFZSA-N,1d,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)hexanoic acid",O=C(CCCC)N([C@@H](CCCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,10.18 ± 0.02,,,10.1016/j.bmc.2012.02.003,Active
SD_088,JTEQEJTWAJZWBA-NRFANRHFSA-N,1e,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)hexanoic acid",O=C(CCC)N([C@@H](CCCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,35.97 ± 0.21,,,10.1016/j.bmc.2012.02.003,Active
SD_089,SJXHNLJBPMFRQH-VWLOTQADSA-N,1f,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-phenylacetamido)hexanoic acid",O=C(CC1=CC=CC=C1)N([C@@H](CCCC)C(O)=O)CC2=CC=C(C3=C(C4=NOC(N4)=O)C=CC=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,17.99 ± 0.13,,,10.1016/j.bmc.2012.02.003,Active
SD_090,SWLQWSIJBDVCIU-DEOSSOPVSA-N,1g,"(S)-2-(N-((2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-phenylacetamido)pentanoic acid",O=C(CC1=CC=CC=C1)N([C@@H](CCC)C(O)=O)CC2=CC=C(C3=C(C4=NOC(N4)=O)C=CC=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,26.52 ± 0.09,,,10.1016/j.bmc.2012.02.003,Active
SD_091,SIVGPWBPJHPSCL-FQEVSTJZSA-N,2,"(S)-2-(N-((5'-fluoro-2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)butyramido)pentanoic acid",O=C(CCC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC(F)=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,20.81 ± 0.12,,,10.1016/j.bmc.2012.02.003,Active
SD_092,ACWBQPMHZXGDFX-QFIPXVFZSA-N,Valsartan,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,60846.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,2.64 ± 0.70,,,10.1016/j.bmc.2012.02.003,Active
SD_093,YOSHYTLCDANDAN-UHFFFAOYSA-N,Irbesartan,"3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one",O=C(CCC)N([C@@H](CCC)C(O)=O)CC1=CC=C(C2=C(C3=NOC(N3)=O)C=CC(F)=C2)C=C1,3749.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,Spontaneously hypertensive rats,0.58 ± 0.22,,,10.1016/j.bmc.2012.02.003,Active
SD_094,RLAWWYSOJDYHDC-BZSNNMDCSA-N,Lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,443,,,10.1016/j.bmc.2013.05.031,Active
SD_095,HDACQVRGBOVJII-JBDAPHQKSA-N,Ramipril,"(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid",O=C(O)[C@@H]1C[C@]2([H])CCC[C@@]2(N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)C)=O)[H],5362129.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,414,,,10.1016/j.bmc.2013.05.031,Active
SD_096,XPCFTKFZXHTYIP-PMACEKPBSA-N,Benazepril,"2-((S)-3-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(CN1C([C@H](CCC2=C1C=CC=C2)N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)=O)O,5362124.0,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,301,,,10.1016/j.bmc.2013.05.031,Active
SD_097,TVLDNLINZRNKES-PBHICJAKSA-N,5f,"(2R,11aS)-10-(3-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=CC(Br)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,398,,,10.1016/j.bmc.2013.05.031,Active
SD_098,UTFPDQLPXOXPSM-PBHICJAKSA-N,5g,"(2R,11aS)-10-(4-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=C(Br)C=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,496,,,10.1016/j.bmc.2013.05.031,Active
SD_099,KWJXQSQVOWQQJY-PBHICJAKSA-N,5r,"(2R,11aS)-2-Hydroxy-10-(3,4,5-trimethoxybenzyl)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(OC)=C(OC)C(OC)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,331,,,10.1016/j.bmc.2013.05.031,Active
SD_100,BEGAJSOBXUVZKP-ABAIWWIYSA-N,5v,"(2R,11aS)-10-((4-Bromothiophen-2-yl)methyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(Br)=CS4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,HEK 293a,Human,281,,,10.1016/j.bmc.2013.05.031,Active
SD_101,RLAWWYSOJDYHDC-BZSNNMDCSA-N,Lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,307,,,10.1016/j.bmc.2013.05.031,Active
SD_102,HDACQVRGBOVJII-JBDAPHQKSA-N,Ramipril,"(2S,3aS,6aS)-1-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid",O=C(O)[C@@H]1C[C@]2([H])CCC[C@@]2(N1C([C@@H](N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)C)=O)[H],5362129.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,392,,,10.1016/j.bmc.2013.05.031,Active
SD_103,XPCFTKFZXHTYIP-PMACEKPBSA-N,Benazepril,"2-((S)-3-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(CN1C([C@H](CCC2=C1C=CC=C2)N[C@@H](CCC3=CC=CC=C3)C(OCC)=O)=O)O,5362124.0,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,358,,,10.1016/j.bmc.2013.05.031,Active
SD_104,TVLDNLINZRNKES-PBHICJAKSA-N,5f,"(2R,11aS)-10-(3-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=CC(Br)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,400.4,,,10.1016/j.bmc.2013.05.031,Active
SD_105,UTFPDQLPXOXPSM-PBHICJAKSA-N,5g,"(2R,11aS)-10-(4-Bromobenzyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC=C(Br)C=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,486.7,,,10.1016/j.bmc.2013.05.031,Active
SD_106,KWJXQSQVOWQQJY-PBHICJAKSA-N,5r,"(2R,11aS)-2-Hydroxy-10-(3,4,5-trimethoxybenzyl)-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(OC)=C(OC)C(OC)=C4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,418.7,,,10.1016/j.bmc.2013.05.031,Active
SD_107,BEGAJSOBXUVZKP-ABAIWWIYSA-N,5v,"(2R,11aS)-10-((4-Bromothiophen-2-yl)methyl)-2-hydroxy-2,3-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H,11aH)-dione",O=C(N1[C@@]2([H])C[C@@H](O)C1)C3=CC=CC=C3N(CC4=CC(Br)=CS4)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,A549b,Human,361,,,10.1016/j.bmc.2013.05.031,Active
SD_108,OQCCQVXGIPCPCB-UHFFFAOYSA-N,1,2-(4-((2-ethyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl) benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC=C3CN4C(CC)=NC5=CC([N+]([O-])=O)=CC=C45,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.00412 ± 0.00115,,,10.1016/j.bmc.2014.02.008,Active
SD_109,AIUSSFIJFZMNEC-UHFFFAOYSA-N,2,2-(4-((2-propyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC=C3CN4C(CCC)=NC5=CC([N+]([O-])=O)=CC=C45,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0054 ± 0.0003,,,10.1016/j.bmc.2014.02.008,Active
SD_110,HVKRZMXJTYIQEY-UHFFFAOYSA-N,3,2-(4-((2-butyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC=C3CN4C(CCCC)=NC5=CC([N+]([O-])=O)=CC=C45,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0010 ± 0.0003,,,10.1016/j.bmc.2014.02.008,Active
SD_111,CSXXIFVIFCAYQC-UHFFFAOYSA-N,4,2-(4-((2-pentyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC=C3CN4C(CCCCC)=NC5=CC([N+]([O-])=O)=CC=C45,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0157 ± 0.0003,,,10.1016/j.bmc.2014.02.008,Active
SD_112,XPPYZFDVVIKEET-UHFFFAOYSA-N,5,2-(5-((2-propyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC(CN4C(CCC)=NC5=CC([N+]([O-])=O)=CC=C45)=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0033 ± 0.0008,,,10.1016/j.bmc.2014.02.008,Active
SD_113,GZKSWGAGHQQNOS-UHFFFAOYSA-N,6,2-(5-((2-butyl-5-nitro-1H-benzo[d]imidazol-1-yl)methyl)-1H-indol-1-yl)benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC(CN4C(CCCC)=NC5=CC([N+]([O-])=O)=CC=C45)=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0051 ± 0.0009,,,10.1016/j.bmc.2014.02.008,Active
SD_114,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,3961.0,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁,Spontaneously hypertensive rats,0.0035 ± 0.0003,,,10.1016/j.bmc.2014.02.008,Active
SD_115,SONNWYBIRXJNDC-VIFPVBQESA-N,Phenylephrine,3-(1-hydroxy-2-(methylamino)ethyl)phenol,OC1=CC(C(CNC)O)=CC=C1,6041.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.0550 ± 0.0094,,10.1016/j.bmc.2015.03.009,Active
SD_116,VCKUSRYTPJJLNI-UHFFFAOYSA-N,Terazosin,"(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone",O=C(C1OCCC1)N2CCN(CC2)C3=NC(N)=C4C=C(C(OC)=CC4=N3)OC,5401.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.0510 ± 0.0105,,10.1016/j.bmc.2015.03.009,Active
SD_117,GWZKQAZNJFCKIR-UHFFFAOYSA-N,10e,1-{4-[4-(bis(4-Fluorophenyl)methyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.3291 ± 0.0413,,10.1016/j.bmc.2015.03.009,Active
SD_118,RFFLBWRKQXJYFL-UHFFFAOYSA-N,10h,1-{4-[4-(2-Chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3Cl)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁A-adrenoceptor,Rats,,0.1382 ± 0.0219,,10.1016/j.bmc.2015.03.009,Active
SD_119,SONNWYBIRXJNDC-VIFPVBQESA-N,Phenylephrine,3-(1-hydroxy-2-(methylamino)ethyl)phenol,OC1=CC(C(CNC)O)=CC=C1,6041.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.006 ± 0.001,,10.1016/j.bmc.2015.03.009,Active
SD_120,VCKUSRYTPJJLNI-UHFFFAOYSA-N,Terazosin,"(4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl)(tetrahydrofuran-2-yl)methanone",O=C(C1OCCC1)N2CCN(CC2)C3=NC(N)=C4C=C(C(OC)=CC4=N3)OC,5401.0,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0005 ± 0.0001,,10.1016/j.bmc.2015.03.009,Active
SD_121,SIJYLSGWXFVBCP-UHFFFAOYSA-N,10d,1-{4-[4-(2-tolyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3C)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0035 ± 0.0004,,10.1016/j.bmc.2015.03.009,Active
SD_122,GWZKQAZNJFCKIR-UHFFFAOYSA-N,10e,1-{4-[4-(bis(4-Fluorophenyl)methyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.1311 ± 0.0113,,10.1016/j.bmc.2015.03.009,Active
SD_123,NNUSMILRKBXCPT-UHFFFAOYSA-N,10f,1-{4-[4-(2-Hydroxyphenyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3O)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.1653 ± 0.0382,,10.1016/j.bmc.2015.03.009,Active
SD_124,BYFPUJBOVOWOEM-UHFFFAOYSA-N,10g,"1-(4-(4-(2,4-difluorophenyl)piperazin-1-yl)butyl)pyrrolidin-2-one hydrochloride",O=C1N(CCCCN2CCN(C3=CC=C(F)C=C3F)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0469 ± 0.0121,,10.1016/j.bmc.2015.03.009,Active
SD_125,RFFLBWRKQXJYFL-UHFFFAOYSA-N,10h,1-{4-[4-(2-Chlorophenyl)piperazin-1-yl]butyl}pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C3=CC=CC=C3Cl)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.0025 ± 0.0005,,10.1016/j.bmc.2015.03.009,Active
SD_126,QTKHTYAETVTSLH-UHFFFAOYSA-N,10i,1-[4-(4-Benzhydrylpiperazin-1-yl)butyl]pyrrolidin-2-one hydrochloride,O=C1N(CCCCN2CCN(C(C3=CC=CC=C3)C4=CC=CC=C4)CC2)CCC1.[H]Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,α₁B-adrenoceptor,Rats,,0.2887 ± 0.0423,,10.1016/j.bmc.2015.03.009,Active
SD_127,XMPDGGPOGJOFIJ-UHFFFAOYSA-N,1,"7,8-dihydroxy-3-methylisochroman-4-one",O=C1C(C)OCC2=C(O)C(O)=CC=C21,,,ChEMBL,In vitro calcium channel blocking assays,yes,reduction of blood pressure,ACE,Renal hypertensive rats.,,,,doi:10.1016/j.bmcl.2008.12.102,Active
SD_128,JPORXYNUKUUBMN-UHFFFAOYSA-N,22,"2-(4-((6,7-dimethoxy-4-methylquinazolin-2-yl)methyl)piperazin-1-yl)benzonitrile",CC1=NC(CN2CCN(C3=CC=CC=C3C#N)CC2)=NC4=CC(OC)=C(OC)C=C41,,,ChEMBL,In vitro calcium channel blocking assays,,,α1-blockers,Rats,,,,10.1016/j.bmcl.2012.08.040,Active
SD_129,KPUQMJLBRHXRTO-UHFFFAOYSA-N,2a,"6,7-dimethoxy-3-(3-methoxy-4-phenoxybenzyl)quinazolin-4(3H)-one",O=C1C2=CC(OC)=C(OC)C=C2N=CN1CC3=CC=C(OC4=CC=CC=C4)C(OC)=C3,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Changes in arterial ring muscle contraction,,Rat mesenteric arterial rings,,0.398 ± 0.103,,10.1016/j.bmcl.2014.10.092,Active
SD_130,CGYDHMUVDZBWMN-UHFFFAOYSA-N,2c,"3-(4-(4-fluorophenoxy)-3-methoxybenzyl)-6,7-dimethoxyquinazolin-4(3H)-one",O=C1C2=CC(OC)=C(OC)C=C2N=CN1CC3=CC=C(OC4=CC=C(F)C=C4)C(OC)=C3,,,ChEMBL,In vitro calcium channel blocking assays,Yes,Changes in arterial ring muscle contraction,,Rat mesenteric arterial rings,,0.251 ± 0.147,,10.1016/j.bmcl.2014.10.092,Active
SD_131,JNLSCNVEDXJZER-UHFFFAOYSA-N,2,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methyl 3-(3,4-dihydroxyphenyl)propanoate",OC1=CC=C(CCC(OCC2=C(Cl)N=C(CCCC)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)=O)C=C1O,,,ChEMBL,In vitro calcium channel blocking assays,,,AT₁  receptor,,,,,doi:10.1016/j.ejmech.2012.01.043,Active
SD_132,PYNRTEKOEHJSAD-UHFFFAOYSA-N,3,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1H-imidazol-5-yl)methyl 3-(3,4-dihydroxyphenyl)propanoate",OC1=CC=C(CCC(OCC2=C([H])N=C(CCCC)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)=O)C=C1O,,,ChEMBL,In vitro calcium channel blocking assays,,,AT₁  receptor,,,,,doi:10.1016/j.ejmech.2012.01.043,Active
SD_133,OITBAZDRCUUJBM-DEOSSOPVSA-N,8r,"(R)-1-((3'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-N-(2-phenylpropyl)-2-propyl-1H-benzo[d]imidazole-6-carboxamide",O=C(C1=CC(C)=C2N=C(CCC)N(CC3=CC=C(C4=CC=CC(C5=NN=NN5)=C4)C=C3)C2=C1)NC[C@H](C)C6=CC=CC=C6,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0011 ± 0.0005,,,10.1016/j.ejmech.2015.09.010,Active
SD_134,ZIYBBIUQJIMSJG-UHFFFAOYSA-N,1h,2-(4-((6-(benzylcarbamoyl)-2-propyl-4-methyl-1H-benzo[d]imidazol-1-yl) methyl)-1H-indol-1-yl) benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC=C3CN4C(CCC)=NC5=C(C)C=C(C(NCC6=CC=CC=C6)=O)C=C45,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,AT₁  receptor,Spontaneously Hypertensive Rats,,,,10.1016/j.ejmech.2019.07.056.,Active
SD_135,LOAFLKPSVPONCQ-UHFFFAOYSA-N,2e,2-(5-((6-(phenethyl carbamoyl)-2-propyl-4-methyl-1H-benzo[d]imidazol-1-yl) methyl) -1H-indol-1-yl) benzoic acid,O=C(O)C1=CC=CC=C1N2C=CC3=C2C=CC(CN4C(CCC)=NC5=C(C)C=C(C(NCCC6=CC=CC=C6)=O)C=C45)=C3,,,ChEMBL,In vitro calcium channel blocking assays,Yes,,AT₁  receptor,Spontaneously Hypertensive Rats,,,,10.1016/j.ejmech.2019.07.056.,Active
SD_136,ADXGNEYLLLSOAR-UHFFFAOYSA-N,4a,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4-dimethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0052,,,https://doi.org/10.1021/jm00030a013,Active
SD_137,UMGWNXVFPXRTJJ-UHFFFAOYSA-N,4b,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4-(trifluoromethyl)-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C(F)(F)F)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.246,,,https://doi.org/10.1021/jm00030a013,Active
SD_138,VOSRNWKPZUPYSM-UHFFFAOYSA-N,5c,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,6-dimethyl-4-(trifluoromethyl)-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C(C)CC1=C(C(F)(F)F)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.032,,,https://doi.org/10.1021/jm00030a013,Active
SD_139,ZCBZIEODXPGTIF-UHFFFAOYSA-N,4d,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4,6,6-tetramethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C(C)(C)CC1=C(C)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.003,,,https://doi.org/10.1021/jm00030a013,Active
SD_140,SPLZVIWJVWAWDZ-UHFFFAOYSA-N,4e,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-ethyl-2-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(CC)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0023,,,https://doi.org/10.1021/jm00030a013,Active
SD_141,GLIKCYUBIISKTN-UHFFFAOYSA-N,4f,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-isopropyl-2-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C(C)C)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.013,,,https://doi.org/10.1021/jm00030a013,Active
SD_142,FTMDBRIMXYJSJX-UHFFFAOYSA-N,4g,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-4-propyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(CCC)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0018,,,https://doi.org/10.1021/jm00030a013,Active
SD_143,KDFBMTBNSCKZAB-UHFFFAOYSA-N,4h,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethyl-4-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C)N=C(CC)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0013,,,https://doi.org/10.1021/jm00030a013,Active
SD_144,WQECOURAYRIDKD-UHFFFAOYSA-N,4i,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-isopropyl-4-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C)N=C(C(C)C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.022,,,https://doi.org/10.1021/jm00030a013,Active
SD_145,HQFLNKUQWCVZMA-UHFFFAOYSA-N,4j,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-2-propyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C)N=C(CCC)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.00135,,,https://doi.org/10.1021/jm00030a013,Active
SD_146,BGSIWQLVFAOOGV-UHFFFAOYSA-N,4k,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(hydroxymethyl)-2-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(CO)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.023,,,https://doi.org/10.1021/jm00030a013,Active
SD_147,DKMLYADVVLIQTK-UHFFFAOYSA-N,4l,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-methyl-7-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-4-carbaldehyde",O=C(C([H])CC1=C(C=O)N=C(C)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0507,,,https://doi.org/10.1021/jm00030a013,Active
SD_148,PYGFPKLNGWVHGK-UHFFFAOYSA-N,4m,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-(hydroxymethyl)-4-methyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",O=C(C([H])CC1=C(C)N=C(CO)N=C21)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.285,,,https://doi.org/10.1021/jm00030a013,Active
SD_149,CRPBWMYAUJNKOV-UHFFFAOYSA-N,31,"8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4-dimethyl-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine",CC(N=C12)=NC(C)=C2CCCN1CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.17,,,https://doi.org/10.1021/jm00030a013,Active
SD_150,SJLUSJJVURDIRZ-UHFFFAOYSA-M,32,"potassium 4'-((2,4-dimethyl-7-oxo-6,7-dihydropyrido[2,3-d]pyrimidin-8(5H)-yl)methyl)-[1,1'-biphenyl]-2-carboxylate",CC(N=C12)=NC(C)=C2CCC(N1CC3=CC=C(C4=CC=CC=C4C(O[K])=O)C=C3)=O.O,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.085,,,https://doi.org/10.1021/jm00030a013,Active
SD_151,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,1,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0347,,,https://doi.org/10.1021/jm00030a013,Active
SD_152,XSHXQLODFJYKON-UHFFFAOYSA-N,4n,"8-((6-(2-(1H-tetrazol-5-yl)phenyl)pyridin-3-yl)methyl)-2,4-dimethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",CC(N=C12)=NC(C)=C2CCC(N1CC3=CN=C(C4=CC=CC=C4C5=NN=NN5)C=C3)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0243,,,https://doi.org/10.1021/jm00030a013,Active
SD_153,PZOLYHWTYZJVKL-UHFFFAOYSA-N,4o,"8-((6-(2-(1H-tetrazol-5-yl)phenyl)pyridin-3-yl)methyl)-2-methyl-4-(trifluoromethyl)-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",CC(N=C[23])=NC(C(F)(F)F)=C@23CCC(N(@23)CC[6]=CN=C(C[13]()=CC=CC=C@13C[22]=NN=NN@22)C=C@7)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0949,,,https://doi.org/10.1021/jm00030a013,Active
SD_154,HPKMJTIQUSGVRH-UHFFFAOYSA-N,4p,"8-((5-(2-(1H-tetrazol-5-yl)phenyl)pyridin-2-yl)methyl)-2,4-dimethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one",CC(N=C12)=NC(C)=C2CCC(N1CC3=NC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,"Rat (anesthetized, ganglion-blocked, AII-infused)",0.0494,,,https://doi.org/10.1021/jm00030a013,Active
SD_155,VQRWTUVJWQDHMN-VLIRHVTKSA-N,3a,(4S)-3-((1-carboxy-3-phenylpropyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0035,,,10.1021/jm00122a003,Active
SD_156,UERNDUXVRTZBPS-YIOYIWSBSA-N,3b,(4S)-3-((1-carboxynonyl)-D-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@@H](C)NC(CCCCCCCC)C(O)=O)N([C@H](C(O)=O)CN1C)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0024,,,10.1021/jm00122a003,Active
SD_157,UERNDUXVRTZBPS-HPNRGHHYSA-N,3c,(4S)-3-((1-carboxynonyl)-L-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCCCCCCC)C(O)=O)N([C@H](C(O)=O)CN1C)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0016,,,10.1021/jm00122a003,Active
SD_158,PVTGPGODYMYICV-LWEDLAQUSA-N,3d,(4S)-3-((2S)-2-((1-carboxynonyl)amino)butanoyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](CC)NC(CCCCCCCC)C(O)=O)N([C@H](C(O)=O)CN1C)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0024,,,10.1021/jm00122a003,Active
SD_159,VFAVNRVDTAPBNR-UFPXDFCQSA-N,3e,(4S)-3-((1-carboxy-3-phenylpropyl)-L-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2C)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0017,,,10.1021/jm00122a003,Active
SD_160,YXKNPBOMMAVIAP-NZEUDUFCSA-N,3f,(4S)-1-butyl-3-((1-carboxy-3-phenylpropyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2CCCC)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0067,,,10.1021/jm00122a003,Active
SD_161,PFDASPRFUYLYPB-VFDRBLODSA-N,3g,(4S)-1-benzyl-3-((1-carboxy-3-methylbutyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CC(C)C)C(O)=O)N([C@H](C(O)=O)CN1CC2=CC=CC=C2)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0021,,,10.1021/jm00122a003,Active
SD_162,FBHXDPZPVJNMKH-NZEUDUFCSA-N,3h,(4S)-1-benzyl-3-((1-carboxy-4-methylpentyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC(C)C)C(O)=O)N([C@H](C(O)=O)CN1CC2=CC=CC=C2)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0033,,,10.1021/jm00122a003,Active
SD_163,CKNHXDLZEFXBNR-SPFPWHRZSA-N,3i,(4S)-1-benzyl-3-((1-carboxynonyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCCCCCCC)C(O)=O)N([C@H](C(O)=O)CN1CC2=CC=CC=C2)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0015,,,10.1021/jm00122a003,Active
SD_164,MMGCSVIXPMTZFM-YSTUSHMSSA-N,3j,(4S)-1-benzyl-3-((2S)-2-((1-carboxynonyl)amino)butanoyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](CC)NC(CCCCCCCC)C(O)=O)N([C@H](C(O)=O)CN1CC2=CC=CC=C2)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0021,,,10.1021/jm00122a003,Active
SD_165,CKJXIEFPECQCPK-GZMMRYBBSA-N,3k,(4S)-1-benzyl-3-((1-carboxy-2-phenylethyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2CC3=CC=CC=C3)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0011,,,10.1021/jm00122a003,Active
SD_166,JUKHDGIMURKPAP-VBHUFULTSA-N,3l,(4S)-1-benzyl-3-((1-carboxy-3-phenylpropyl)-D-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@@H](C)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2CC3=CC=CC=C3)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0024,,,10.1021/jm00122a003,Active
SD_167,JUKHDGIMURKPAP-LIXNJBPUSA-N,3m,(4S)-1-benzyl-3-((1-carboxy-3-phenylpropyl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2CC3=CC=CC=C3)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0017,,,10.1021/jm00122a003,Active
SD_168,YSRVQAHAXCLQNP-YSTUSHMSSA-N,3n,(4S)-1-benzyl-3-((2S)-2-((1-carboxy-3-phenylpropyl)amino)butanoyl)-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](CC)NC(CCC1=CC=CC=C1)C(O)=O)N([C@H](C(O)=O)CN2CC3=CC=CC=C3)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0023,,,10.1021/jm00122a003,Active
SD_169,LZFZMUMEGBBDTC-QEJZJMRPSA-N,enalaprilat,((S)-1-carboxy-3-phenylpropyl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)C)=O)O,5462501.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,0.0029,,,10.1021/jm00122a003,Active
SD_170,ITHJRJBUTDRAMW-AQOJYXMDSA-N,3o,(4S)-3-((1-ethoxy-1-oxodecan-2-yl)-L-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCCCCCCC)C(OCC)=O)N([C@H](C(O)=O)CN1C)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,5.1,,,10.1021/jm00122a003,Active
SD_171,KLZWOWYOHUKJIG-VFDRBLODSA-N,3p,(4S)-3-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@H](C)NC(CCC1=CC=CC=C1)C(OCC)=O)N([C@H](C(O)=O)CN2C)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,9.9,,,10.1021/jm00122a003,Active
SD_172,KLZWOWYOHUKJIG-BXCKNWRKSA-N,3q,(4S)-3-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)-D-alanyl)-1-methyl-2-oxoimidazolidine-4-carboxylic acid,O=C([C@@H](C)NC(CCC1=CC=CC=C1)C(OCC)=O)N([C@H](C(O)=O)CN2C)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,,,,10.1021/jm00122a003,Active
SD_173,UUXIQSOSENHQFC-SXJSUMJGSA-N,3r,(4S)-1-benzyl-3-((1-ethoxy-1-oxodecan-2-yl)-L-alanyl)-2-oxoimidazolidine-4-carboxylic acid--methane (1/1),O=C([C@H](C)NC(CCCCCCCC)C(OCC)=O)N([C@H](C(O)=O)CN1CC2=CC=CC=C2)C1=O.C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,2.2,,,10.1021/jm00122a003,Active
SD_174,,3s,,,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Spontaneously hypertensive rats,7.9,,,10.1021/jm00122a003,Active
SD_175,ZNGXOKMCRDQBON-UHFFFAOYSA-N,5a,3-hydrazinyl-6-phenylpyridazine,NNC1=NN=C(C2=CC=CC=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,206,,,10.1016/j.ejmech.2015.12.015,Active
SD_176,AZCTXHPEZWKVGD-UHFFFAOYSA-N,5b,3-(4-chlorophenyl)-6-hydrazinylpyridazine,ClC1=CC=C(C2=NN=C(NN)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,275,,,10.1016/j.ejmech.2015.12.015,Active
SD_177,USQCPILVLRVMCO-UHFFFAOYSA-N,5c,3-hydrazinyl-6-(2-methoxyphenyl)pyridazine,COC1=C(C2=NN=C(NN)C=C2)C=CC=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,279,,,10.1016/j.ejmech.2015.12.015,Active
SD_178,ASGDUFOXUMFAMV-UHFFFAOYSA-N,5d,3-hydrazinyl-6-(4-methoxyphenyl)pyridazine,COC1=CC=C(C2=NN=C(NN)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,235,,,10.1016/j.ejmech.2015.12.015,Active
SD_179,SIDDZDIUZDOWCS-UHFFFAOYSA-N,6a,3-(1H-Imidazol-1-yl)-6-phenylpyridazine,C1(N2C=CN=C2)=NN=C(C3=CC=CC=C3)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,273,,,10.1016/j.ejmech.2015.12.015,Active
SD_180,YWYCETYLBLGALY-UHFFFAOYSA-N,6b,3-(4-Chlorophenyl)-6-(1H-imidazol-1-yl)pyridazine,ClC1=CC=C(C2=NN=C(N3C=CN=C3)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,255,,,10.1016/j.ejmech.2015.12.015,Active
SD_181,QLSQPBAQEHBYQV-UHFFFAOYSA-N,6c,3-(1H-Imidazol-1-yl)-6-(2-methoxyphenyl)pyridazine,COC1=CC=CC=C1C2=NN=C(N3C=CN=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,205,,,10.1016/j.ejmech.2015.12.015,Active
SD_182,BGVKFGUIMWOVAB-UHFFFAOYSA-N,6d,3-(1H-Imidazol-1-yl)-6-(4-methoxyphenyl)pyridazine,COC1=CC=C(C2=NN=C(N3C=CN=C3)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,259,,,10.1016/j.ejmech.2015.12.015,Active
SD_183,KCPSHTZFQSQCBJ-UHFFFAOYSA-N,7a,6-(Pyrrolidin-1-yl)phenylpyridazine,C1(C2=C(N3CCCC3)C=CC=C2)=NN=CC=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,235,,,10.1016/j.ejmech.2015.12.015,Active
SD_184,XFPHUPQYBRXMAM-UHFFFAOYSA-N,7b,3-(4-Chlorophenyl)-6-(pyrrolidin-1-yl)pyridazine,ClC1=CC=C(C2=NN=C(N3CCCC3)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,300,,,10.1016/j.ejmech.2015.12.015,Active
SD_185,AJXGNWLLZPXIGJ-UHFFFAOYSA-N,7c,3-(2-Methoxyphenyl)-6-(pyrrolidin-1-yl)pyridazine,COC1=CC=CC=C1C2=NN=C(N3CCCC3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,284,,,10.1016/j.ejmech.2015.12.015,Active
SD_186,BAAIMUNDXAWEBW-UHFFFAOYSA-N,8a,"3-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-phenylpyridazine",CC1=CC(C)=NN1C2=NN=C(C3=CC=CC=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,198,,,10.1016/j.ejmech.2015.12.015,Active
SD_187,DJBUCMQPADJSPF-UHFFFAOYSA-N,8b,"3-(4-Chlorophenyl)6-(3,5-dimethyl-1H-pyrazol-1-yl)pyridazine",CC1=CC(C)=NN1C2=NN=C(C3=CC=C(Cl)C=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,213,,,10.1016/j.ejmech.2015.12.015,Active
SD_188,UGNAXOASOOSMIV-UHFFFAOYSA-N,8c,"3-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(2-methoxyphenyl)pyridazine",COC1=CC=CC=C1C2=NN=C(N3N=C(C)C=C3C)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,299,,,10.1016/j.ejmech.2015.12.015,Active
SD_189,STWCADKYBUYKSR-UHFFFAOYSA-N,8d,"3-(3,5-Dimethyl-1H-pyrazol-1-yl)-6-(4-methoxyphenyl)pyridazine",COC1=CC=C(C2=NN=C(N3N=C(C)C=C3C)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,323,,,10.1016/j.ejmech.2015.12.015,Active
SD_190,KEZUUUJPAJUBOD-UHFFFAOYSA-N,9a,5-Amino-1-(6-phenylpyridazin-3-yl)-1H-pyrazole-4-carbonitrile,N#CC1=C(N)N(C2=NN=C(C3=CC=CC=C3)C=C2)N=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,287,,,10.1016/j.ejmech.2015.12.015,Active
SD_191,SWZLEMCSZZKCPN-UHFFFAOYSA-N,9b,5-Amino-1-[6-(4-chlorophenyl)pyridazin-3-yl]-1H-pyrazole-4-carbonitrile,N#CC1=C(N)N(C2=NN=C(C3=CC=C(Cl)C=C3)C=C2)N=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,310,,,10.1016/j.ejmech.2015.12.015,Active
SD_192,MMMVCNMYQBJJQD-UHFFFAOYSA-N,9c,5-Amino-1-[6-(2-methoxyphenyl)pyridazin-3-yl]-1H-pyrazole-4-carbonitrile,N#CC1=C(N)N(C2=NN=C(C3=CC=CC=C3OC)C=C2)N=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,316,,,10.1016/j.ejmech.2015.12.015,Active
SD_193,XMYLAAJYHDWSFK-UHFFFAOYSA-N,9d,5-Amino-1-[6-(4-methoxyphenyl)pyridazin-3-yl]-1H-pyrazole-4-carbonitrile,N#CC1=C(N)N(C2=NN=C(C3=CC=C(OC)C=C3)C=C2)N=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,260,,,10.1016/j.ejmech.2015.12.015,Active
SD_194,YNQBAEWBKQOHEO-UHFFFAOYSA-N,10a,Ethyl 5-amino-1-(6-phenylpyridazin-3-yl)-1H-pyrazole-4-carboxylate,O=C(C1=C(N)N(C2=NN=C(C3=CC=CC=C3)C=C2)N=C1)OCC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,254,,,10.1016/j.ejmech.2015.12.015,Active
SD_195,XLTABBPJALUMHY-UHFFFAOYSA-N,10b,Ethyl 5-amino-1-[6-(4-chlorophenyl)pyridazin-3-yl]-1H-pyrazole-4-carboxylate,O=C(C1=C(N)N(C2=NN=C(C3=CC=C(Cl)C=C3)C=C2)N=C1)OCC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,230,,,10.1016/j.ejmech.2015.12.015,Active
SD_196,LWWNOEHXASZHBZ-UHFFFAOYSA-N,10c,Ethyl 5-amino-1-[6-(2-methoxyphenyl)pyridazin-3-yl]-1H-pyrazole-4-carboxylate,O=C(C1=C(N)N(C2=NN=C(C3=CC=CC=C3OC)C=C2)N=C1)OCC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,225,,,10.1016/j.ejmech.2015.12.015,Active
SD_197,CKSQOSBKKJQVOC-UHFFFAOYSA-N,10d,"Ethyl 5-amino-1-[6-(4-methoxyphenyl)pyridazin-3-yl]-1H-pyrazole-4-
carboxylate",O=C(C1=C(N)N(C2=NN=C(C3=CC=C(OC)C=C3)C=C2)N=C1)OCC,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,216,,,10.1016/j.ejmech.2015.12.015,Active
SD_198,IZLGQJQFBOQPSZ-UHFFFAOYSA-N,11a,2-[6-(4-Chlorophenyl)pyridazin-3-yl]-N-cyclohexylhydrazine-1-carboxamide,O=C(NNC1=NN=C(C2=CC=C(Cl)C=C2)C=C1)NC3CCCCC3,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,177,,,10.1016/j.ejmech.2015.12.015,Active
SD_199,HSGCUAAQNSHIOW-UHFFFAOYSA-N,11b,N-Cyclohexyl-2-[6-(2-methoxyphenyl)pyridazin-3-yl]hydrazine-1-carboxamide,O=C(NNC1=NN=C(C2=CC=CC=C2OC)C=C1)NC3CCCCC3,,,,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,206,,,10.1016/j.ejmech.2015.12.015,
SD_200,QFSHTDJHBQUAKL-UHFFFAOYSA-N,11c,2-[6-(4-Chlorophenyl)pyridazin-3-yl]-N-phenylhydrazine-1-carboxamide,O=C(NNC1=NN=C(C2=CC=C(Cl)C=C2)C=C1)NC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,207,,,10.1016/j.ejmech.2015.12.015,Active
SD_201,NKRIMBCGUYEIFR-UHFFFAOYSA-N,12a,3-(4-Chlorophenyl)-6-{2-[4-(trifluoromethyl)benzylidene]hydrazinyl}pyridazine,FC(C1=CC=C(C=C1)/C=N/NC2=NN=C(C3=CC=C(Cl)C=C3)C=C2)(F)F,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,209,,,10.1016/j.ejmech.2015.12.015,Active
SD_202,DJWCLIVSBKAKQT-UHFFFAOYSA-N,12b,"3-(4-Methoxyphenyl)-6-{2-[4-(trifluoromethyl)benzylidene]hydrazinyl}
pyridazine",FC(C1=CC=C(C=C1)/C=N/NC2=NN=C(C3=CC=C(OC)C=C3)C=C2)(F)F,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,248,,,10.1016/j.ejmech.2015.12.015,Active
SD_203,DGLZDVBCGPIKJE-UHFFFAOYSA-N,12c,3-(4-Chlorophenyl)-6-[2-(4-methoxybenzylidene)hydrazinyl]pyridazine,COC1=CC=C(C=C1)/C=N/NC2=NN=C(C3=CC=C(Cl)C=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,217,,,10.1016/j.ejmech.2015.12.015,Active
SD_204,GXGWILZHEOYUNK-UHFFFAOYSA-N,12d,3-[2-(4-Methoxybenzylidene)hydrazinyl] 6-(4-methoxyphenyl)pyridazine,COC1=CC=C(C2=NN=C(N/N=C/C3=CC=C(OC)C=C3)C=C2)C=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,200,,,10.1016/j.ejmech.2015.12.015,Active
SD_205,RAQWVUGDHGKVPB-UHFFFAOYSA-N,12e,"3-(4-Chlorophenyl)-6-[2-(2,4-dimethoxybenzylidene)hydrazinyl]pyridazine",COC1=CC=C(C(OC)=C1)/C=N/NC2=NN=C(C3=CC=C(Cl)C=C3)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,205,,,10.1016/j.ejmech.2015.12.015,Active
SD_206,PPNDSUXAKPKZFU-UHFFFAOYSA-N,12f,"3-[2-(2,4-Dimethoxybenzylidene)hydrazinyl]-6-(2-methoxyphenyl)pyridazine",COC1=CC=CC=C1C2=NN=C(N/N=C/C3=CC=C(OC)C=C3OC)C=C2,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,259,,,10.1016/j.ejmech.2015.12.015,Active
SD_207,QWYQEVZILXKETF-UHFFFAOYSA-N,12g,"3-(4-Chlorophenyl)-6-[2-(3,4,5-trimethoxybenzylidene)hydrazinyl]pyridazine",COC1=C(OC)C(OC)=CC(/C=N/NC2=NN=C(C3=CC=C(Cl)C=C3)C=C2)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,255,,,10.1016/j.ejmech.2015.12.015,Active
SD_208,HSZMRGCPLJILDN-UHFFFAOYSA-N,12h,"3-(2-Methoxyphenyl)-6-[2-(3,4,5-trimethoxybenzylidene)hydrazinyl]pyridazine",COC1=C(OC)C(OC)=CC(/C=N/NC2=NN=C(C3=CC=CC=C3OC)C=C2)=C1,,,ChEMBL,In vitro calcium channel blocking assays,Yes,relaxation of the vascular smooth muscle,,,221,,,10.1016/j.ejmech.2015.12.015,Active
SD_209,HRWCVUIFMSZDJS-SZMVWBNQSA-N,19a,"(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)[C@H](C)N[C@H](C(OCC)=O)CCC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.092,,,10.1021/jm00127a033,Active
SD_210,HRWCVUIFMSZDJS-SZMVWBNQSA-N,spirapril,"(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",CCOC([C@@H](N[C@H](C(N1CC2(SCCS2)C[C@H]1C(O)=O)=O)C)CCC3=CC=CC=C3)=O,5311447.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.67,,,10.1021/jm00127a033,Active
SD_211,FMMDBLMCSDRUPA-BPUTZDHNSA-N,spiraprilat,"(S)-7-(((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)[C@H](C)N[C@H](C(O)=O)CCC3=CC=CC=C3,3033702.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.0008,,,10.1021/jm00127a033,Active
SD_212,FMMDBLMCSDRUPA-IMJJTQAJSA-N,26,"(S)-7-(((R)-1-carboxy-3-phenylpropyl)-L-alanyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)[C@H](C)N[C@@H](C(O)=O)CCC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.0009,,,10.1021/jm00127a033,Active
SD_213,XLDXYHRDTJBVEB-BZSNNMDCSA-N,36,"(S)-7-((S)-5-amino-2-(((S)-1-carboxy-3-phenylpropyl)amino)pentanoyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)[C@H](CCCN)N[C@H](C(O)=O)CCC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.2,,,10.1021/jm00127a033,Active
SD_214,FQISISIMLFMVEY-IRXDYDNUSA-N,19b,"(S)-7-(((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)glycyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid",O=C(N1[C@H](C(O)=O)CC2(SCCS2)C1)C([H])N[C@H](C(OCC)=O)CCC3=CC=CC=C3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.0005,,,10.1021/jm00127a033,Active
SD_215,GBXSMTUPTTWBMN-XIRDDKMYSA-N,enalapril,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,5388962.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,1.273,,,10.1021/jm00127a033,Active
SD_216,LZFZMUMEGBBDTC-QEJZJMRPSA-N,enalaprilat,((S)-1-carboxy-3-phenylpropyl)-L-alanyl-L-proline,O=C(C[3:S=I]HN(CCC@4)C(C[S=N]H(NC[S=N]H(CCC[16]=CC=CC=C@16)C(O)=O)C)=O)O,5462501.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.0026,,,10.1021/jm00127a033,Active
SD_217,RLAWWYSOJDYHDC-BZSNNMDCSA-N,lisinopril,((S)-1-carboxy-3-phenylpropyl)-L-lysyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)CCCCN)=O)O,5362119.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.00012,,,10.1021/jm00127a033,Active
SD_218,FAKRSMQSSFJEIM-RQJHMYQMSA-N,captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Rat,0.00129,,,10.1021/jm00127a033,Active
SD_219,FOJRYJADYAOGSC-WIHSUSGWSA-N,7a ,1-[2-[1-(Ethoxycarbonyl)-3-phenylpropoxy]-1-oxopropyl]-L-proline,O=C(O)[C@H]1N(C(C(OC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.22,,,10.1021/jm00147a030,Active
SD_220,KJGGXEGBIHOCTB-DFJPGDIZSA-N,7b ,(1S)-2-(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)oxy)propanoyl)octahydro-1H-isoindole-1-carboxylic acid,O=C(O)[C@H]1N(C(C(OC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3C1CCCC3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.024,,,10.1021/jm00147a030,Active
SD_221,MPECDBDZHABNOE-IQVJOUTCSA-N,7c,(3S)-2-(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)oxy)propanoyl)decahydroisoquinoline-3-carboxylic acid,O=C(O)[C@H]1N(C(C(OC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3C(C1)CCCC3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.014,,,10.1021/jm00147a030,Active
SD_222,JFGSPCGBBXYKKA-WIHSUSGWSA-N,8a ,(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)thio)propanoyl)-L-proline,O=C(O)[C@H]1N(C(C(SC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",2.9,,,10.1021/jm00147a030,Active
SD_223,LPXVVEDQPNJYOF-SIWZUTFBSA-N,8b ,(4R)-3-(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)thio)propanoyl)thiazolidine-4-carboxylic acid,O=C(O)[C@H]1N(C(C(SC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CSC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",4.8,,,10.1021/jm00147a030,Active
SD_224,VLZZWEPWFKXZDG-DFJPGDIZSA-N,8c,(1S)-2-(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)thio)propanoyl)octahydro-1H-isoindole-1-carboxylic acid,O=C(O)[C@H]1N(C(C(SC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3C1CCCC3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",2,,,10.1021/jm00147a030,Active
SD_225,FSCJXQKDXZLROY-LPBNZCGVSA-N,8d ,"(3S)-2-(2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)thio)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid",O=C(O)[C@H]1N(C(C(SC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)CC3=CC=CC=C3C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.46,,,10.1021/jm00147a030,Active
SD_226,JFRPFZJSSBSVOO-BLZCZZARSA-N,9a,(2-(1-carboxy-3-phenylpropoxy)propanoyl)-L-proline,O=C(O)[C@H]1N(C(C(OC(C(O)=O)CCC2=CC=CC=C2)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.11,,,10.1021/jm00147a030,Active
SD_227,LQWNYMDUNAIMSA-YHDJDMAPSA-N,9b ,"(3S)-2-(2-(1-carboxy-3-phenylpropoxy)propanoyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid",O=C(O)[C@H]1N(C(C(OC(C(O)=O)CCC2=CC=CC=C2)C)=O)CC3=CC=CC=C3C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.086,,,10.1021/jm00147a030,Active
SD_228,JVZOJVSKVSEJNC-BLZCZZARSA-N,10a,(2-((1-carboxy-3-phenylpropyl)thio)propanoyl)-L-proline,O=C(O)[C@H]1N(C(C(SC(C(O)=O)CCC2=CC=CC=C2)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.58,,,10.1021/jm00147a030,Active
SD_229,PFTMAIADZAEIOG-BITBVIDPSA-N,10b ,(1S)-2-(2-((1-carboxy-3-phenylpropyl)thio)propanoyl)octahydro-1H-isoindole-1-carboxylic acid,O=C(O)[C@H]1N(C(C(SC(C(O)=O)CCC2=CC=CC=C2)C)=O)CC3C1CCCC3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.14,,,10.1021/jm00147a030,Active
SD_230,IRFLEJXVMMQAGR-UHFFFAOYSA-N,10c ,1-(2-((1-carboxy-3-phenylpropyl)thio)propanamido)cyclopentane-1-carboxylic acid,O=C(O)C1(NC(C(SC(C(O)=O)CCC2=CC=CC=C2)C)=O)CCCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",,,,10.1021/jm00147a030,Active
SD_231,LESVLYGNJXROMX-FCCSPCGPSA-N,10d,(2S)-2-((1-((1-formyl-4-phenylcyclohexyl)amino)-1-oxopropan-2-yl)thio)-4-phenylbutanoic acid,O=C([C@@H](SC(C)C(NC1(C=O)CCC(C2=CC=CC=C2)CC1)=O)CCC3=CC=CC=C3)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",,,,10.1021/jm00147a030,Active
SD_232,YMMJWPHJWAMKSF-WTZHAPHZSA-N,11,(2S)-1-(2-(((1-ethoxy-4-phenylbutan-2-yl)thio)oxy)propanoyl)octahydro-1H-indole-2-carboxylic acid,O=C([C@H]1N(C(C(OSC(CCC2=CC=CC=C2)COCC)C)=O)C3CCCCC3C1)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.22,,,10.1021/jm00147a030,Active
SD_233,UNTJKVPEDMTDAL-WGJHYSAWSA-N,13,(2-(((1-ethoxy-4-phenylbutan-2-yl)sulfinyl)oxy)propanoyl)-L-proline,O=C(O)[C@H]1N(C(C(OS(C(CCC2=CC=CC=C2)COCC)=O)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",,,,10.1021/jm00147a030,Active
SD_234,AJXNWOLLHVBCNI-WIHSUSGWSA-N,14,1-[2-[[ 1-(Ethoxycarbonyl)-3-phenylpropyl]-sulfonyl]-1-oxopropyl]- L- proline,O=C(O)[C@H]1N(C(C(S(=O)(C(C(OCC)=O)CCC2=CC=CC=C2)=O)C)=O)CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",,,,10.1021/jm00147a030,Active
SD_235,XUTWHCANXPTUTG-PBNVNTQYSA-N,CI-906,"(3S)-2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)alanyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dicarboxylic acid",O=C(O)[C@H]1N(C(C(NC(C(OCC)=O)CCC2=CC=CC=C2)C)=O)C(C(O)=O)C3=CC=CC=C3C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.0083,,,10.1021/jm00147a030,Active
SD_236,"(3S)-2-((1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dicarboxylic acid",CI-906f,"(3S)-2-((1-carboxy-3-phenylpropyl)alanyl)-1,2,3,4-tetrahydroisoquinoline-1,3-dicarboxylic acid",O=C(O)[C@H]1N(C(C(NC(C(O)=O)CCC2=CC=CC=C2)C)=O)C(C(O)=O)C3=CC=CC=C3C1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.0028,,,10.1021/jm00147a030,Active
SD_237,AYECQRAXWBGXSZ-WJGSZSDCSA-N,CI-907 ,(1S)-2-((1-ethoxy-1-oxo-4-phenylbutan-2-yl)alanyl)octahydro-1H-isoindole-1-carboxylic acid,O=C([C@H]1N(C(C(NC(CCC2=CC=CC=C2)C(OCC)=O)C)=O)CC3CCCCC13)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.1,,,10.1021/jm00147a030,Active
SD_238,SGWDRFQPAPSOTL-GOTSBHOMSA-N,CI-907f,"2-((S)-3-(((S)-6-(((benzyloxy)carbonyl)amino)-1-ethoxy-1-oxohexan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C([C@H]1N(C(C(NC(CCC2=CC=CC=C2)C(O)=O)C)=O)CC3CCCCC13)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.0026,,,10.1021/jm00147a030,Active
SD_239,GBXSMTUPTTWBMN-XIRDDKMYSA-N,enalapril,((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,5388962.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.14,,,10.1021/jm00147a030,Active
SD_240,AWWFNGKCTHHBSZ-WPKBUWHJSA-N,MK-4229 ,((S)-1-carboxy-3-phenylpropyl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(O)=O)C)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.0031,,,10.1021/jm00147a030,Active
SD_241,FAKRSMQSSFJEIM-RQJHMYQMSA-N,captopril,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,44093.0,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,"Conscious Goldblatt hypertensive rats (two kidney, one clip)",0.013,,,10.1021/jm00147a030,Active
SD_242,AXTCRUUITQKBAV-KGLIPLIRSA-N,5a,"((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-lysine",O=C(O)CN1C([C@H](N[C@H](C(O)=O)CCCCN)CCC2=CC=CC=C21)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.007,,,10.1021/jm00149a010,Active
SD_243,BJPLYVULVZSLCO-CVEARBPZSA-N,5b,"2-((R)-3-(((S)-6-amino-1-ethoxy-1-oxohexan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(CN1C([C@H](N[C@@H](CCCCN)C(OCC)=O)CCC2=CC=CC=C21)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.04,,,10.1021/jm00149a010,Active
SD_244,WKNDKOZNFFZORF-RTWAWAEBSA-N,5c,"N6-((benzyloxy)carbonyl)-N2-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-lysine",O=C(CN1C([C@H](N[C@@H](CCCCNC(OCC2=CC=CC=C2)=O)C(O)=O)CCC3=CC=CC=C31)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.013,,,10.1021/jm00149a010,Active
SD_245,SGWDRFQPAPSOTL-PKTZIBPZSA-N,5d,"2-((R)-3-(((S)-6-(((benzyloxy)carbonyl)amino)-1-ethoxy-1-oxohexan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@@H](CCCCNC(OCC3=CC=CC=C3)=O)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.015,,,10.1021/jm00149a010,Active
SD_246,SWAFCAYLJAGDHL-SJORKVTESA-N,5e,"N6-(tert-butoxycarbonyl)-N2-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-lysine",O=C(O)[C@H](CCCCNC(OC(C)(C)C)=O)N[C@@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.004,,,10.1021/jm00149a010,Active
SD_247,XPUBRIORWWZECV-PKTZIBPZSA-N,5f,"2-((R)-3-(((S)-1-ethoxy-1-oxo-6-((phenoxymethyl)amino)hexan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@@H](CCCCNCOC3=CC=CC=C3)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_248,BSQTWZJZKHVTTN-MSOLQXFVSA-N,5g,"O-benzyl-N-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-serine",O=C(O)[C@H](COCC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.01,,,10.1021/jm00149a010,Active
SD_249,YAVUFYQECTUCKD-UXHICEINSA-N,5h,"2-((R)-3-(((S)-3-(benzyloxy)-1-ethoxy-1-oxopropan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@@H](COCC3=CC=CC=C3)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_250,XCJANLVRPWZEHK-MSOLQXFVSA-N,5i,"S-benzyl-N-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-cysteine",O=C(O)[C@H](CSCC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.029,,,10.1021/jm00149a010,Active
SD_251,AIMVOTANDHXULA-UXHICEINSA-N,5j,"2-((R)-3-(((R)-3-(benzylthio)-1-ethoxy-1-oxopropan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@@H](CSCC3=CC=CC=C3)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_252,DHQXBKIHWXJRQL-MOPGFXCFSA-N,5k,"N-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-S-phenethyl-L-cysteine",O=C(O)[C@H](CSCCC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.007,,,10.1021/jm00149a010,Active
SD_253,ZXTSTZUERUGEPU-SJORKVTESA-N,5l,"N-((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-S-phenyl-L-cysteine",O=C(O)[C@H](CSC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.004,,,10.1021/jm00149a010,Active
SD_254,DGPRMEPFNWGGKJ-MOPGFXCFSA-N,5m,"2-((R)-3-(((R)-1-ethoxy-1-oxo-3-(phenylthio)propan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@@H](CSC3=CC=CC=C3)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_255,VUCYCNRONPBINV-IAGOWNOFSA-N,5n,"((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-D-phenylalanine",O=C(O)[C@@H](CC1=CC=CC=C1)N[C@@H]2CCC3=CC=CC=C3N(CC(O)=O)C2=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.0085,,,10.1021/jm00149a010,Active
SD_256,QICHJVAYOFKCAC-OALUTQOASA-N,5o,"2-((S)-3-(((S)-1-ethoxy-1-oxo-3-phenylpropan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C([C@@H](N[C@H](C(OCC)=O)CC2=CC=CC=C2)CCC3=CC=CC=C31)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_257,ZGRWPIBEYNPMJC-MOPGFXCFSA-N,5p,"(S)-2-(((S)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)amino)-3-(2H-indol-3-yl)propanoic acid",O=C(O)[C@@H](N[C@@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O)CC3=C4C=CC=CC4=NC3,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.013,,,10.1021/jm00149a010,Active
SD_258,UHZFVGXJPUTNHL-NHCUHLMSSA-N,5q,"2-((R)-3-(((R)-1-ethoxy-3-(2H-indol-3-yl)-1-oxopropan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@H](CC3=C4C=CC=CC4=NC3)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.54,,,10.1021/jm00149a010,Active
SD_259,XXQDAAMXJXLXDD-KGLIPLIRSA-N,5r,"((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-leucine",CC(C)C[C@@H](C(O)=O)N[C@@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.045,,,10.1021/jm00149a010,Active
SD_260,DIAKVMVEHAUODE-LSDHHAIUSA-N,5s,"2-((S)-3-(((S)-1-methoxy-4-methyl-1-oxopentan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@H](N[C@H](CC(C)C)C(OC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,1,,,10.1021/jm00149a010,Active
SD_261,OJBUNWORDYSDBG-KGLIPLIRSA-N,5t,"(S)-2-(((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)amino)hexanoic acid",CCCC[C@H](N[C@@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O)C(O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.0005,,,10.1021/jm00149a010,Active
SD_262,CLYQVSLBVFEZBT-HZPDHXFCSA-N,5u,"2-((R)-3-(((R)-1-ethoxy-1-oxohexan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@H](CCCC)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,2.6,,,10.1021/jm00149a010,Active
SD_263,AOIGNBXQHAONIJ-OLZOCXBDSA-N,5v,"((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-L-methionine",O=C(CN1C([C@@H](CCC2=CC=CC=C21)N[C@@H](CCSC)C(O)=O)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.0065,,,10.1021/jm00149a010,Active
SD_264,ZEFRGVLOSJHNPV-HUUCEWRRSA-N,5w,"2-((R)-3-(((R)-1-ethoxy-4-(methylthio)-1-oxobutan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",O=C(O)CN1C2=CC=CC=C2CC[C@@H](N[C@H](CCSC)C(OCC)=O)C1=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_265,VVIRFPRKWLIIJA-OLZOCXBDSA-N,5x,"(S)-2-(((R)-1-(carboxymethyl)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)amino)pentanoic acid",CCC[C@H](N[C@@H]1CCC2=CC=CC=C2N(CC(O)=O)C1=O)C(O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,0.006,,,10.1021/jm00149a010,Active
SD_266,OGYIBHXBSVMHGN-GJZGRUSLSA-N,5y,"2-((S)-3-(((S)-1-ethoxy-1-oxopentan-2-yl)amino)-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)acetic acid",,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,Dogs,,,,10.1021/jm00149a010,Active
SD_267,VXOCIBBWDLKODX-UHFFFAOYSA-N,12,(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CNC(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.21,,,10.1021/jm00379a013,Active
SD_268,KHXJUBSGGXLCFM-UHFFFAOYSA-N,13,N-(3-mercapto-2-methylpropanoyl)-N-methylglycine,O=C(O)CN(C(C(C)CS)=O)C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.13,,,10.1021/jm00379a013,Active
SD_269,NEFQJOOROFDSGD-UHFFFAOYSA-N,14,N-ethyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(CC)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.075,,,10.1021/jm00379a013,Active
SD_270,CXBHQULQNOOTII-UHFFFAOYSA-N,15,N-isopropyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C(C)C)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.072,,,10.1021/jm00379a013,Active
SD_271,OZPRNBYPMCBPMW-UHFFFAOYSA-N,16,N-(3-(acetylthio)propanoyl)-N-isopropylglycine,[H]C(CSC(C)=O)C(N(C(C)C)C([H])C(O)=O)=O.C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,5.9,,,10.1021/jm00379a013,Active
SD_272,OQXFHYHUXJEPQI-UHFFFAOYSA-N,17,N-cyclopropyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.03,,,10.1021/jm00379a013,Active
SD_273,IUFNBYIQGPSJHJ-UHFFFAOYSA-N,18,N-(3-(acetylthio)-2-methylpropanoyl)-N-cyclopropylglycine,O=C(O)CN(C(C(C)CSC(C)=O)=O)C1CC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.54,,,10.1021/jm00379a013,Active
SD_274,GOENAUONFPAZBX-UHFFFAOYSA-N,19,N-cyclopropyl-N-(3-mercaptopropanoyl)alanine,O=C(O)C(C)N(C1CC1)C(CCS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.079,,,10.1021/jm00379a013,Active
SD_275,FZXAXWFWGFLJIC-UHFFFAOYSA-N,20,N-(3-(acetylthio)propanoyl)-N-cyclopropylalanine,O=C(O)C(C)N(C(CCSC(C)=O)=O)C1CC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.22,,,10.1021/jm00379a013,Active
SD_276,HAHASCMUEWBAFT-UHFFFAOYSA-N,21,N-cyclobutyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.018,,,10.1021/jm00379a013,Active
SD_277,PBODOLPKDOKHOV-UHFFFAOYSA-N,22,N-(3-(acetylthio)-2-methylpropanoyl)-N-cyclobutylglycine,O=C(O)CN(C(C(C)CSC(C)=O)=O)C1CCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.22,,,10.1021/jm00379a013,Active
SD_278,ALRGMGVUAWHELZ-UHFFFAOYSA-N,23a(R+S),N-cyclopentyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.018,,,10.1021/jm00379a013,Active
SD_279,ALRGMGVUAWHELZ-UHFFFAOYSA-N,23b,N-cyclopentyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.016,,,10.1021/jm00379a013,Active
SD_280,UPEZQPMUYZATJA-UHFFFAOYSA-N,24,N-(3-(acetylthio)-2-methylpropanoyl)-N-cyclopentylglycine,O=C(O)CN(C(C(C)CSC(C)=O)=O)C1CCCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.082,,,10.1021/jm00379a013,Active
SD_281,FGFHICIYRMWGIF-UHFFFAOYSA-N,25,N-cyclohexyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C1CCCCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.035,,,10.1021/jm00379a013,Active
SD_282,DJTUXLGDNAMVJS-UHFFFAOYSA-N,26,N-(3-(acetylthio)-2-methylpropanoyl)-N-cyclohexylglycine,O=C(O)CN(C(C(C)CSC(C)=O)=O)C1CCCCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.27,,,10.1021/jm00379a013,Active
SD_283,BDYGMDMPZALDDI-UHFFFAOYSA-N,27,N-cycloheptyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(C(C(C)CS)=O)C1CCCCCC1,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.031,,,10.1021/jm00379a013,Active
SD_284,GWOKPYPGELGLLB-UHFFFAOYSA-N,28,N-(3-(acetylthio)-2-methylpropanoyl)-N-cycloheptylglycine,O=C(O)CN(C1CCCCCC1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.088,,,10.1021/jm00379a013,Active
SD_285,USAXCUHSDRCEKI-NVEZCULWSA-N,29,"N-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-yl)-N-(3-mercapto-2-methylpropanoyl)glycine",O=C(O)CN([C@H]1[C@](C2)([H])CC[C@]2([H])C1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.032,,,10.1021/jm00379a013,
SD_286,ANWXKCAWLVVCJP-HGDNVOPISA-N,30,"N-(3-(acetylthio)-2-methylpropanoyl)-N-((1R,2R,4S)-bicyclo[2.2.1]heptan-2-yl)glycine",O=C(O)CN(C(C(C)CSC(C)=O)=O)C[6:S=N]HC[S=I](C[12])(H)CCC[S=I]@12(H)C@7,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.02,,,10.1021/jm00379a013,
SD_287,BGSKHHVRRAUKPB-UHFFFAOYSA-N,31,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(tricyclo[4.2.0.01,3]octan-5-yl)glycine",O=C(O)CN(C(C(C)CSC(C)=O)=O)C1CC2CC32CCC13,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.052,,,10.1021/jm00379a013,
SD_288,YNTNUAUVNZTXCX-IOCOHYSWSA-N,32,"N-(3-mercapto-2-methylpropanoyl)-N-(2-((3S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)ethyl)glycine",O=C(O)CN(CC[C@@H]1CC2CC(C2(C)C)C1C)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.44,,,10.1021/jm00379a013,
SD_289,ZIIWVXPQVFNPJJ-UHFFFAOYSA-N,33,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(2-(6,6-dimethylbicyclo[3.1.1]heptan-3-yl)ethyl)glycine",O=C(O)CN(CCC1CC2CC(C2(C)C)C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.085,,,10.1021/jm00379a013,
SD_290,AJDGOTYEQFIRKP-XHLRWWMNSA-N,34,"N-(3-mercapto-2-methylpropanoyl)-N-(((3S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)methyl)glycine",O=C(O)CN(C[C@H]1CC(C2(C)C)CC2C1C)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.16,,,10.1021/jm00379a013,
SD_291,SLKDSLAWMQSCJY-GDNWTEEJSA-N,35,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(((3S)-2,6,6-trimethylbicyclo[3.1.1]heptan-3-yl)methyl)glycine",O=C(O)CN(C[C@H]1CC(C2(C)C)CC2C1C)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.14,,,10.1021/jm00379a013,
SD_292,KXRIOZZBVJVHQC-VPGYJZJUSA-N,36,"N-(3-(acetylthio)-2-methylpropanoyl)-N-((2R)-6,6-dimethylbicyclo[3.1.1]heptan-2-yl)glycine",O=C(O)CN([C@H]1C(C2(C)C)CC2CC1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.045,,,10.1021/jm00379a013,
SD_293,KSVRHWYBXURNCF-UHFFFAOYSA-N,37,"N-(2,3-dihydro-1H-inden-2-yl)-N-(3-mercapto-2-methylpropanoyl)glycine",O=C(O)CN(C(C1)CC2=C1C=CC=C2)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.031,,,10.1021/jm00379a013,
SD_294,XENJKTJZYMBEBZ-UHFFFAOYSA-N,38,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(2,3-dihydro-1H-inden-2-yl)glycine",O=C(O)CN(C(C1)CC2=C1C=CC=C2)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.34,,,10.1021/jm00379a013,
SD_295,TZTHZQINDIJPGY-UHFFFAOYSA-N,39,N-(3-mercapto-2-methylpropanoyl)-N-(2-methoxyethyl)glycine,O=C(O)CN(CCOC)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.095,,,10.1021/jm00379a013,
SD_296,BRFHDYHPVSODIF-UHFFFAOYSA-N,40,N-(3-mercapto-2-methylpropanoyl)-N-(3-(methylthio)propyl)glycine,O=C(O)CN(CCCSC)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.055,,,10.1021/jm00379a013,
SD_297,CULZBNYMCVLGBF-UHFFFAOYSA-N,41,N-(3-(acetylthio)-2-methylpropanoyl)-N-(3-(methylthio)propyl)glycine,O=C(O)CN(CCCSC)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.9,,,10.1021/jm00379a013,
SD_298,CITSYFVNXVVLPL-UHFFFAOYSA-N,42,N-(3-mercapto-2-methylpropanoyl)-N-(2-(tetrahydrofuran-2-yl)ethyl)glycine,O=C(O)CN(CCC1CCCO1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.13,,,10.1021/jm00379a013,
SD_299,JJGOAVUFOUNTLF-UHFFFAOYSA-N,43,N-(3-(acetylthio)-2-methylpropanoyl)-N-(2-(tetrahydrofuran-2-yl)ethyl)glycine,O=C(O)CN(CCC1CCCO1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,1.9,,,10.1021/jm00379a013,
SD_300,GKZRLQNLSYIUMB-UHFFFAOYSA-N,44,N-(2-(furan-2-yl)ethyl)-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(CCC1=CC=CO1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.17,,,10.1021/jm00379a013,
SD_301,WRGIXWVPTQUNNZ-UHFFFAOYSA-N,45,N-(3-(acetylthio)-2-methylpropanoyl)-N-(2-(furan-2-yl)ethyl)glycine,O=C(O)CN(CCC[17]=CC=CO@17)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.7,,,10.1021/jm00379a013,
SD_302,FWUJXVTVXVCWLQ-UHFFFAOYSA-N,46,N-(3-mercapto-2-methylpropanoyl)-N-(2-(thiophen-2-yl)ethyl)glycine,O=C(O)CN(CCC1=CC=CS1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.055,,,10.1021/jm00379a013,
SD_303,OSWOLDPQZJTLPW-UHFFFAOYSA-N,47,N-(3-(acetylthio)-2-methylpropanoyl)-N-(2-(thiophen-2-yl)ethyl)glycine,O=C(O)CN(CCC1=CC=CS1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.75,,,10.1021/jm00379a013,
SD_304,UVSVKNSUELWONQ-UHFFFAOYSA-N,48,"N-(1,1-dioxidotetrahydrothiophen-3-yl)-N-(3-mercapto-2-methylpropanoyl)glycine",O=C(O)CN(C1CCS(C1)(=O)=O)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.28,,,10.1021/jm00379a013,
SD_305,AJFQVKUJEYTCQF-UHFFFAOYSA-N,49,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(1,1-dioxidotetrahydrothiophen-3-yl)glycine",O=C(O)CN(C1CCS(C1)(=O)=O)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.28,,,10.1021/jm00379a013,
SD_306,MBUNQOGWMVDDDM-UHFFFAOYSA-N,50,N-((1-ethylpyrrolidin-2-yl)methyl)-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(CC1N(CC)CCC1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.64,,,10.1021/jm00379a013,
SD_307,OZHXHHKPWBGXNA-UHFFFAOYSA-N,51,N-allyl-N-(3-mercapto-2-methylpropanoyl)glycine,O=C(O)CN(CC=C)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.27,,,10.1021/jm00379a013,
SD_308,KSGDJHIHNLVWIO-UHFFFAOYSA-N,52,N-(3-(acetylthio)-2-methylpropanoyl)-N-allylglycine,O=C(O)CN(CC=C)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,4.5,,,10.1021/jm00379a013,
SD_309,KYSRQHDFTNPRNI-UHFFFAOYSA-N,53,N-(3-mercapto-2-methylpropanoyl)-N-phenylglycine,O=C(O)CN(C1=CC=CC=C1)C(C(C)CS)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.3,,,10.1021/jm00379a013,
SD_310,ZOLOJYDPQCQSLJ-UHFFFAOYSA-N,54,N-(3-(acetylthio)-2-methylpropanoyl)-N-phenylglycine,O=C(O)CN(C1=CC=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.3,,,10.1021/jm00379a013,
SD_311,HXHYDYDBVKXKSC-UHFFFAOYSA-N,55,2-((4-mercapto-3-methylbut-1-en-2-yl)(o-tolyl)amino)-1-(l1-oxidaneyl)ethan-1-one,O=C(O)CN(C[17]=C(C)C=CC=C@17)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.12,,,10.1021/jm00379a013,
SD_312,NXOWMKUZYDYGFZ-UHFFFAOYSA-N,56,N-(3-(acetylthio)-2-methylpropanoyl)-N-(o-tolyl)glycine,O=C(O)CN(C1=C(C)C=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.55,,,10.1021/jm00379a013,
SD_313,KRBVEPZLJICFID-UHFFFAOYSA-N,57,2-((4-mercapto-3-methylbut-1-en-2-yl)(m-tolyl)amino)-1-(l1-oxidaneyl)ethan-1-one,O=C([O])CN(C1=CC(C)=CC=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.19,,,10.1021/jm00379a013,
SD_314,KYLMCMYDQDSVTM-UHFFFAOYSA-N,58,N-(3-(acetylthio)-2-methylpropanoyl)-N-(m-tolyl)glycine,O=C(O)CN(C1=CC(C)=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.75,,,10.1021/jm00379a013,
SD_315,AQXMEVMYHNHRJA-UHFFFAOYSA-N,59,2-((4-mercapto-3-methylbut-1-en-2-yl)(p-tolyl)amino)-1-(l1-oxidaneyl)ethan-1-one,O=C([O])CN(C1=CC=C(C)C=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.005,,,10.1021/jm00379a013,
SD_316,SGBISVZAEWIZDT-UHFFFAOYSA-N,60,N-(3-(acetylthio)-2-methylpropanoyl)-N-(p-tolyl)glycine,O=C(O)CN(C1=CC=C(C)C=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.13,,,10.1021/jm00379a013,
SD_317,AXLSRWNJCJLBGC-UHFFFAOYSA-N,61,"2-((3,5-dimethylphenyl)(4-mercapto-3-methylbut-1-en-2-yl)amino)-1-(l1-oxidaneyl)ethan-1-one",O=C([O])CN(C1=CC(C)=CC(C)=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.044,,,10.1021/jm00379a013,
SD_318,IGSRBHAOMLDLQK-UHFFFAOYSA-N,62,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(3,5-dimethylphenyl)glycine",O=C(O)CN(C1=CC(C)=CC(C)=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.044,,,10.1021/jm00379a013,
SD_319,DUZRYPPMYXFQCS-UHFFFAOYSA-N,63,"2-((2,3-dihydro-1H-inden-5-yl)(4-mercapto-3-methylbut-1-en-2-yl)amino)-1-(l1-oxidaneyl)ethan-1-one",O=C([O])CN(C1=CC2=C(CCC2)C=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.33,,,10.1021/jm00379a013,
SD_320,OMYMGFLPGNJKPU-UHFFFAOYSA-N,64,"N-(3-(acetylthio)-2-methylpropanoyl)-N-(2,3-dihydro-1H-inden-5-yl)glycine",O=C(O)CN(C1=CC2=C(CCC2)C=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.048,,,10.1021/jm00379a013,
SD_321,WNBTXZFHTRRRBT-UHFFFAOYSA-N,65,N-(3-(acetylthio)-2-methylpropanoyl)-N-(3-methoxyphenyl)glycine,O=C(O)CN(C1=CC(OC)=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.11,,,10.1021/jm00379a013,
SD_322,UZMWMQIZJBDFQU-UHFFFAOYSA-N,66,N-(3-(acetylthio)-2-methylpropanoyl)-N-(3-(methylthio)phenyl)glycine,O=C(O)CN(C1=CC(SC)=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0,,,10.1021/jm00379a013,
SD_323,HSEOJPROQPVZIC-UHFFFAOYSA-N,67,N-(3-(acetylthio)-2-methylpropanoyl)-N-(3-fluorophenyl)glycine,O=C(O)CN(C1=CC(F)=CC=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.051,,,10.1021/jm00379a013,
SD_324,PMDNRSJARFTVGH-UHFFFAOYSA-N,68,2-((4-fluorophenyl)(4-mercapto-3-methylbut-1-en-2-yl)amino)-1-(l1-oxidaneyl)ethan-1-one,O=C([O])CN(C1=CC=C(F)C=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.023,,,10.1021/jm00379a013,
SD_325,OFXXBGPTOQAYRW-UHFFFAOYSA-N,69,N-(3-(acetylthio)-2-methylpropanoyl)-N-(4-fluorophenyl)glycine,O=C(O)CN(C1=CC=C(F)C=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.6,,,10.1021/jm00379a013,
SD_326,HGXGSGUNJQVINN-UHFFFAOYSA-N,70,2-((4-butylphenyl)(4-mercapto-3-methylbut-1-en-2-yl)amino)-1-(l1-oxidaneyl)ethan-1-one,O=C([O])CN(C1=CC=C(CCCC)C=C1)C(C(C)CS)=C,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.19,,,10.1021/jm00379a013,
SD_327,QRVPNSMLMPOHRT-UHFFFAOYSA-N,71,N-(3-(acetylthio)-2-methylpropanoyl)-N-(4-butylphenyl)glycine,O=C(O)CN(C1=CC=C(CCCC)C=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.064,,,10.1021/jm00379a013,
SD_328,AWJRIAGDGSEDMH-UHFFFAOYSA-N,72,N-(3-(acetylthio)-2-methylpropanoyl)-N-(4-isopropylphenyl)glycine,CC.O=C(O)CN(C1=CC=C(C(C)C)C=C1)C(C(C)CSC(C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.06,,,10.1021/jm00379a013,
SD_329,NLBPJLBGGISTIW-UHFFFAOYSA-N,73,"N-cyclopentyl-N-(3-((3,3-dimethylbutanoyl)thio)-2-methylpropanoyl)glycine",O=C(O)CN(C1CCCC1)C(C(C)CSC(CC(C)(C)C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,15,,,10.1021/jm00379a013,
SD_330,XRKXJJYSKUIIEN-UHFFFAOYSA-N,74a,N-cyclopentyl-N-(2-methyl-3-(pivaloylthio)propanoyl)glycine,O=C(O)CN(C1CCCC1)C(C(C)CSC(C(C)(C)C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,3.7,,,10.1021/jm00379a013,
SD_331,XRKXJJYSKUIIEN-NSHDSACASA-N,74b,(R)-N-cyclopentyl-N-(2-methyl-3-(pivaloylthio)propanoyl)glycine,O=C(O)CN(C1CCCC1)C([C@@H](C)CSC(C(C)(C)C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,>100,,,10.1021/jm00379a013,
SD_332,XRKXJJYSKUIIEN-LLVKDONJSA-N,74c,(S)-N-cyclopentyl-N-(2-methyl-3-(pivaloylthio)propanoyl)glycine,O=C(O)CN(C1CCCC1)C([C@H](C)CSC(C(C)(C)C)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,3.6,,,10.1021/jm00379a013,
SD_333,FAKRSMQSSFJEIM-RQJHMYQMSA-N,2,((S)-3-mercapto-2-methylpropanoyl)-L-proline,C[C@@H](C(N1CCC[C@H]1C(O)=O)=O)CS,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,0.017,,,10.1021/jm00379a013,
SD_334,GBXSMTUPTTWBMN-XIRDDKMYSA-N,3,((S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-L-alanyl-L-proline,O=C([C@H]1N(CCC1)C([C@@H](N[C@@H](CCC2=CC=CC=C2)C(OCC)=O)C)=O)O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,8,,,10.1021/jm00379a013,
SD_335,YTGJWQPHMWSCST-UHFFFAOYSA-N,4,(2-mercaptopropanoyl)glycine,SC(C)C(NCC(O)=O)=O,,,ChEMBL,In vitro calcium channel blocking assays,No,,ACE,spontaneously hypertensive rats,1.9,,,10.1021/jm7011563,
SD_336,YFWXFHNZGKNDBC-UHFFFAOYSA-N,2a,"3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=CC(C)=NC2=C1N=C(CC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0004,,,10.1021/jm7011563,
SD_337,VRBPVOFTDKMURN-UHFFFAOYSA-N,2b,"3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-5,7-dimethyl-2-propyl-3H-imidazo[4,5-b]pyridine",CC1=CC(C)=NC2=C1N=C(CCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0008,,,10.1021/jm7011563,
SD_338,LGLZPVSJGCVURZ-UHFFFAOYSA-N,7a,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-pentyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.108,,,10.1021/jm7011563,
SD_339,JKWVJTQZCHOGJJ-UHFFFAOYSA-N,7b,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-isobutyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CC(C)C)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,2.3,,,10.1021/jm7011563,
SD_340,BWKIOYBQMPZRBR-UHFFFAOYSA-N,7c,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.018,,,10.1021/jm7011563,
SD_341,LSBPDXVQAPQQIU-UHFFFAOYSA-N,7d,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-isopentyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCC(C)C)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.124,,,10.1021/jm7011563,
SD_342,LGLZPVSJGCVURZ-UHFFFAOYSA-N,7e,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-pentyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC=CC=C51,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.053,,,10.1021/jm7011563,
SD_343,MUTVQKXFOBCEHY-UHFFFAOYSA-N,7f,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-benzyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CC2=CC=CC=C2)N(CC3=CC=C(C4=CC=CC=C4C5=NNN=N5)C=C3)C6=NC=CC=C61,,,ChEMBL,In vitro calcium channel blocking assays,No,,AT₁  receptor,,>3,,,10.1021/jm7011563,
SD_344,PZSFAMFZXZAOHP-UHFFFAOYSA-N,7g,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethyl-6-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",CC(C=C1)=NC(N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=C1C(N2CC)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,1.87,,,10.1021/jm7011563,
SD_345,VVTDICDCDGMMCA-UHFFFAOYSA-N,7h,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-methyl-2-propyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",CC(C=C1)=NC(N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=C1C(N2CCC)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.291,,,10.1021/jm7011563,
SD_346,GCRHVXYVQWLSJN-UHFFFAOYSA-N,7i,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",CC(C=C1)=NC(N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=C1C(N2CCCC)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.081,,,10.1021/jm7011563,
SD_347,BNYWWXJJGSMGLA-UHFFFAOYSA-N,7J,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-chloro-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",ClC(C=C1)=NC(N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=C1C(N2CCCC)=O,,,,In vitro calcium channel blocking assays,,,,,0.168,,,,
SD_348,TVOTUWSBAXNGEN-UHFFFAOYSA-N,7k,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-chloro-5-fluoro-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",ClC(C(F)=C1)=NC(N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=C1C(N2CCCC)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.427,,,10.1021/jm7011563,
SD_349,HHWOGTSOLUKYML-UHFFFAOYSA-N,7l,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-5-fluoro-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(N[18]CCCC)C[16]=C(N=CC(F)=C@16)N(@18)CC(C=C[12])=CC=C@12C[5]=C(C[23]=NNN=N@23)C=CC=C@6,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.07,,,10.1021/jm7011563,
SD_350,HHWOGTSOLUKYML-UHFFFAOYSA-N,7m,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-benzyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(N1CCCC)C2=C(N=CC(F)=C2)N1CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.076,,,10.1021/jm7011563,
SD_351,YJVNUQUHBWRFGG-UHFFFAOYSA-N,7n,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-methoxy-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(N1CCCC)C2=C(N=C(OC)C=C2)N1CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.258,,,10.1021/jm7011563,
SD_352,CNYVHWIEPZCCRX-UHFFFAOYSA-N,7o,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-(methylamino)-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(N1CCCC)C2=C(N=C(NC)C=C2)N1CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.124,,,10.1021/jm7011563,
SD_353,FJGJHIPSLRVYTH-UHFFFAOYSA-N,7p,"1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-6-(thiomorpholin-2-yl)-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C1N(CCCC)N(CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2)C5=NC(C6CNCCS6)=CC=C51,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.6,,,10.1021/jm7011563,
SD_354,FPLCSYVKKXEZJD-UHFFFAOYSA-N,7q,"7-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-6-propyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",O=C(N1CCC)C2=C(N=CC=C2)C1CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4.C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,>3,,,10.1021/jm7011563,
SD_355,NEJFAMVNQNXGLG-UHFFFAOYSA-N,8a,"2-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1-butyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(C(C=CC=N1)=C1N2CCCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.039,,,10.1021/jm7011563,
SD_356,KTPNSHNJZAUHMY-UHFFFAOYSA-N,8b,"2-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1-butyl-6-methyl-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(C(C=CC(C)=N1)=C1N2CCCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.09,,,10.1021/jm7011563,
SD_357,VNUKLVWIQNHPIW-UHFFFAOYSA-N,8c,"2-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1-butyl-6-chloro-1,2-dihydro-3H-pyrazolo[3,4-b]pyridin-3-one",O=C(C(C=CC(Cl)=N1)=C1N2CCCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.461,,,10.1021/jm7011563,
SD_358,YDOKIGAEIAQDLH-UHFFFAOYSA-N,8d,YDOKIGAEIAQDLH-UHFFFAOYSA-N,O=C(C(C=CC=N1)=C1C2)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,>10,,,10.1021/jm7011563,
SD_359,DJLLOPXCLRKKSC-UHFFFAOYSA-N,8e,"6-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-7-ethyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",O=C(C(C=CC=N1)=C1C2CC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,>10,,,10.1021/jm7011563,
SD_360,PBVMNRPKLPSZNJ-UHFFFAOYSA-N,8f,"6-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-7-propyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",O=C(C(C=CC=N1)=C1C2CCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.154,,,10.1021/jm7011563,
SD_361,PNNHQGDWIIUMFS-UHFFFAOYSA-N,8g,"6-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-7-butyl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one",O=C(C(C=CC=N1)=C1C2CCCC)N2CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.095,,,10.1021/jm7011563,
SD_362,YNUJCFNPWBMWKD-UHFFFAOYSA-N,18,YNUJCFNPWBMWKD-UHFFFAOYSA-N,O=C(N1CCCC)C2=C(N=CC=C2)N1CC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4.C=[N].CCCC,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.598,,,10.1021/jm7011563,
SD_363,SXLBZZWNBKTXEL-UHFFFAOYSA-N,35a,"3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methoxy)-1-propyl-1H-pyrazolo[3,4-b]pyridine",CCCN1C2=C(C=CC=N2)C(OCC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=N1,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.146,,,10.1021/jm7011563,
SD_364,NLLLHDYGVUXTQW-UHFFFAOYSA-N,35b,"3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methoxy)-1-butyl-1H-pyrazolo[3,4-b]pyridine",CCCCN1C2=C(C=CC=N2)C(OCC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=N1,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.254,,,10.1021/jm7011563,
SD_365,NRGOMEBSHWHSCJ-UHFFFAOYSA-N,45,"4-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methoxy)-2-butylphthalazin-1(2H)-one",O=C1C2=C(C=CC=C2)C(OCC(C=C3)=CC=C3C4=C(C5=NNN=N5)C=CC=C4)=NN1CCCC,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.114,,,10.1021/jm7011563,
SD_366,CZGUSIXMZVURDU-UHFFFAOYSA-N,Ang II,"2-((1H-imidazol-4-yl)methyl)-17-amino-5-(sec-butyl)-1-(2-((1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-guanidinopropyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic acid",NC(C(NC(CCCNC(N)=N)C(NC(C(C)C)C(NC(CC1=CC=C(O)C=C1)C(NC(C(CC)C)C(NC(CC2=CNC=N2)C(N3C(C(NC(CC4=CC=CC=C4)C(O)=O)=O)CCC3)=O)=O)=O)=O)=O)=O)CC(O)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0004,,,10.1021/jm7011563,
SD_367,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,Losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0067,,,10.1021/jm7011563,
SD_368,ACWBQPMHZXGDFX-QFIPXVFZSA-N,Valsartan,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0034,,,10.1021/jm7011563,
SD_369,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.024,,,10.1016/S0960-894X(01)81117-3,
SD_370,MKVAWNKOBRIWFI-QHCPKHFHSA-N,3,"methyl N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-leucinate",CCCCC(N([C@@H](CC(C)C)C(OC)=O)CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.068,,,10.1016/S0960-894X(01)81117-3,
SD_371,WXYMNFMZFLUCSS-UHFFFAOYSA-N,4a,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoylglycine",CCCCC(N(CC(O)=O)CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,,,,10.1016/S0960-894X(01)81117-3,
SD_372,HFMATXSUPNSWTN-UHFFFAOYSA-N,4b,"2-(N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)pentanamido)-3-(4-fluorophenyl)propanoic acid",O=C(O)C(CC1=CC=C(F)C=C1)N(CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)C(CCCC)=O,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.14,,,10.1016/S0960-894X(01)81117-3,
SD_373,QFCDZSRVDUYPKU-HNNXBMFYSA-N,4c,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-alanine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.011,,,10.1016/S0960-894X(01)81117-3,
SD_374,QFCDZSRVDUYPKU-HNNXBMFYSA-N,4d(R),"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-alanine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.104,,,10.1016/S0960-894X(01)81117-3,
SD_375,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4e,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.0014,,,10.1016/S0960-894X(01)81117-3,
SD_376,ACWBQPMHZXGDFX-QFIPXVFZSA-N,valsataran,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",CC([C@H](N(CC1=CC=C(C2=C(C3=NN=NN3)C=CC=C2)C=C1)C(CCCC)=O)C(O)=O)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,,,,10.1016/S0960-894X(01)81117-3,
SD_377,ACWBQPMHZXGDFX-QFIPXVFZSA-N,4f(R),"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoyl-L-valine",O=C(O)[C@@H](N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)C(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.1,,,10.1016/S0960-894X(01)81117-3,
SD_378,PJKUCOOPPKPDJQ-UHFFFAOYSA-N,4g,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-pentanoylphenylalanine",O=C(O)C(N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)CC4=CC=CC=C4,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.5,,,10.1016/S0960-894X(01)81117-3,
SD_379,LAEWWLKDUYJDOB-UHFFFAOYSA-N,5,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-(1-amino-4-methyl-1-oxopentan-2-yl)pentanamide",O=C(N)C(N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)CC(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.003,,,10.1016/S0960-894X(01)81117-3,
SD_380,OBXYUGKGGNDCHX-UHFFFAOYSA-N,6,"N-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-N-(1-hydroxy-4-methylpentan-2-yl)pentanamide",OCC(N(CC1=CC=C(C2=CC=CC=C2C3=NN=NN3)C=C1)C(CCCC)=O)CC(C)C,,,,In vitro calcium channel blocking assays,No,,AT₁  receptor,,0.068,,,10.1016/S0960-894X(01)81117-3,
SD_381,QYIPOXNEMKTMBY-VCUCLJMBSA-N,8b,2-(2-(4-(3-(5-Benzyliden-4-oxo-2-(phenylimino)thiazolidin-3-yl)-2-hydroxypropylamino)benzoyl)hydrazinyl)-2-oxoethyl nitrate,O=[N+]([O-])OCC(NNC(C1=CC=C(NCC(O)CN(C/2=O)/C(SC2=C\C3=CC=CC=C3)=N\C4=CC=CC=C4)C=C1)=O)=O,, ,,In vitro calcium channel blocking assays,Yes,Relaxation of the isolated rat thoracic aorta ring,Ca2+ channel,,,,,10.1016/j.bmc.2008.10.032,
SD_382,LDTPGUBUVSYFHT-MXDAADOSSA-N,8c,2-(2-(4-(2-Hydroxy-3-(5-(4-hydroxybenzyliden)-4-oxo-2-(phenylimino)thiazolidin-3-yl)propylamino)benzoyl)hydrazinyl)-2-oxoethyl nitrate,O=[N+]([O-])OCC(NNC(C1=CC=C(NCC(O)CN(C/2=O)/C(SC2=C\C3=CC=C(O)C=C3)=N\C4=CC=CC=C4)C=C1)=O)=O,,Pubchem,,In vitro calcium channel blocking assays,Yes,Relaxation of the isolated rat thoracic aorta ring,Ca2+ channel,,,,,10.1016/j.bmc.2008.10.032,
SD_383,DGBMTRDXBIUCKR-ADKUPVABSA-N,8d,2-(2-(4-(2-Hydroxy-3-(5-(2-hydroxybenzyliden)-4-oxo-2-(phenylimino)thiazolidin-3-yl)propylamino)benzoyl)hydrazinyl)-2-oxoethyl nitrate,O=[N+]([O-])OCC(NNC(C1=CC=C(NCC(O)CN(C/2=O)/C(SC2=C/C3=CC=CC=C3O)=N\C4=CC=CC=C4)C=C1)=O)=O,,Pubchem,,In vitro calcium channel blocking assays,Yes,Relaxation of the isolated rat thoracic aorta ring,Ca2+ channel,,,,,10.1016/j.bmc.2008.10.032,
SD_384,PZFVWPFXYLISTC-PZRUTKPKSA-N,8f,"2-(2-(4-(2-Hydroxy-3-(4-oxo-2-(phenylimino)-5-(3,4,5-trimethoxybenzyliden)thiazolidin-3-yl)propylamino)benzoyl)-hydrazinyl)-2-oxoethyl nitrate",O=[N+]([O-])OCC(NNC(C1=CC=C(NCC(O)CN(C/2=O)/C(SC2=C\C3=CC(OC)=C(OC)C(OC)=C3)=N\C4=CC=CC=C4)C=C1)=O)=O,,Pubchem,,In vitro calcium channel blocking assays,Yes,Relaxation of the isolated rat thoracic aorta ring,Ca2+ channel,,,,,10.1016/j.bmc.2008.10.032,
SD_385,MYCQCVOMONBCIS-UHFFFAOYSA-N,5,"isopropyl 3-(dimethylcarbamoyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(C(C(C1=CC=CC([N+]([O-])=O)=C1)N2C(N(C)C)=O)=C(C)NC2=O)OC(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,3.2,,,10.1021/jm00106a048,
SD_386,DEZXGDQOCSRRMP-UHFFFAOYSA-N,6,"isopropyl 6-methyl-3-(methylcarbamoyl)-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(C(C(C1=CC=CC([N+]([O-])=O)=C1)N2C(NC)=O)=C(C)NC2=O)OC(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.016,,,10.1021/jm00106a048,
SD_387,JTILQSIVPVPOTG-UHFFFAOYSA-N,7,"isopropyl 3-carbamoyl-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(C(C(C1=CC=CC([N+]([O-])=O)=C1)N2C(N)=O)=C(C)NC2=O)OC(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.012,,,10.1021/jm00106a048,
SD_388,UDLOBPWBPRYOTP-UHFFFAOYSA-N,10,"isopropyl 6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(C(C(C1=CC=CC([N+]([O-])=O)=C1)N2[H])=C(C)NC2=O)OC(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,1.58,,,10.1021/jm00106a048,
SD_389,NGEFFDYYNIRRME-UHFFFAOYSA-N,17a,"ethyl 3-carbamoyl-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OCC)=O)N(C(N)=O)C1C2=CC([N+]([O-])=O)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.039,,,10.1021/jm00106a048,
SD_390,CIKULUBECDKHFL-UHFFFAOYSA-N,17b,"methyl 3-carbamoyl-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC)=O)N(C(N)=O)C1C2=CC([N+]([O-])=O)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.88,,,10.1021/jm00106a048,
SD_391,DZEHOACOQBAKNP-UHFFFAOYSA-N,17c,"isopropyl 3-(ethylcarbamoyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(NCC)=O)C1C2=CC([N+]([O-])=O)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.013,,,10.1021/jm00106a048,
SD_392,OAKKHOGCUWAIRH-UHFFFAOYSA-N,17d,"isopropyl 3-(isopropylcarbamoyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(NC(C)C)=O)C1C2=CC([N+]([O-])=O)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.06,,,10.1021/jm00106a048,
SD_393,YIOFPEQCJMBGBV-UHFFFAOYSA-N,17e,"isopropyl 3-(benzylcarbamoyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(NCC2=CC=CC=C2)=O)C1C3=CC([N+]([O-])=O)=CC=C3,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.003,,,10.1021/jm00106a048,
SD_394,YMQZIAHMOKVIEJ-UHFFFAOYSA-N,17f,"isopropyl 3-(2-(benzyl(methyl)amino)ethyl)-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(CCN(CC2=CC=CC=C2)C)C1C3=CC([N+]([O-])=O)=CC=C3,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.002,,,10.1021/jm00106a048,
SD_395,FCVDBJYRGKUHBC-UHFFFAOYSA-N,17g,"isopropyl 3-carbamoyl-6-methyl-4-(2-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C([N+]([O-])=O)C=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.02,,,10.1021/jm00106a048,
SD_396,IYHLOUNZKOVOAZ-UHFFFAOYSA-N,17h,"isopropyl 3-carbamoyl-6-methyl-2-oxo-4-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=CC(C(F)(F)F)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,1.67,,,10.1021/jm00106a048,
SD_397,LFRCBGUYFGOVRU-UHFFFAOYSA-N,17i,"isopropyl 3-carbamoyl-6-methyl-2-oxo-4-(2-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(C(F)(F)F)C=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.044,,,10.1021/jm00106a048,
SD_398,NEORKLPGSMVSDS-UHFFFAOYSA-N,17j,"isopropyl 3-carbamoyl-4-(3-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=CC(Cl)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.04,,,10.1021/jm00106a048,
SD_399,MJHVURZZWVIJRK-UHFFFAOYSA-N,17,"isopropyl 3-carbamoyl-4-(2-chlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(Cl)C=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.034,,,10.1021/jm00106a048,
SD_400,LSGMRPZJMHTJQV-UHFFFAOYSA-N,17l,"isopropyl 4-(3-bromophenyl)-3-carbamoyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=CC(Br)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.055,,,10.1021/jm00106a048,
SD_401,CUFVZMKVSMNLPY-UHFFFAOYSA-N,17m,"isopropyl 4-(2-bromophenyl)-3-carbamoyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(Br)C=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.031,,,10.1021/jm00106a048,
SD_402,MVLYZUNXOOVSTL-UHFFFAOYSA-N,17n,"isopropyl 3-carbamoyl-4-(2,6-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(Cl)C=CC=C2Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.083,,,10.1021/jm00106a048,
SD_403,XCKMRLIWGNQJMU-UHFFFAOYSA-N,17o,"isopropyl 3-carbamoyl-4-(2,3-dichlorophenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(Cl)C(Cl)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.043,,,10.1021/jm00106a048,
SD_404,GCLSFQQANUXQHJ-UHFFFAOYSA-N,17p,"isopropyl 3-carbamoyl-4-(2,3-di(1,2,3-oxadiazol-4-yl)phenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)C1C2=C(C3=CON=N3)C(C4=CON=N4)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.082,,,10.1021/jm00106a048,
SD_405,JTILQSIVPVPOTG-CYBMUJFWSA-N,20a,"isopropyl (R)-3-carbamoyl-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(NC(C)=C1C(OC(C)C)=O)N(C(N)=O)[C@@H]1C2=CC([N+]([O-])=O)=CC=C2,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.0085,,,10.1021/jm00106a048,
SD_406,JTILQSIVPVPOTG-ZDUSSCGKSA-N,20b,"isopropyl (S)-3-carbamoyl-6-methyl-4-(3-nitrophenyl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate",O=C(C1=C(C)NC(N(C(N)=O)[C@H]1C2=CC=CC([N+]([O-])=O)=C2)=O)OC(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,3.79,,,10.1021/jm00106a048,
SD_407,HYIMSNHJOBLJNT-UHFFFAOYSA-N,Nifedipine ,"dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate",O=C(C1=C(C)NC(C)=C(C(OC)=O)C1C2=CC=CC=C2[N+]([O-])=O)OC,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.0025,,,10.1021/jm00106a048,
SD_408,HTIQEAQVCYTUBX-UHFFFAOYSA-N,Amlodipine ,"3-ethyl 5-methyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate",O=C(OCC)C1=C(NC(C)=C(C1C2=C(Cl)C=CC=C2)C(OC)=O)COCCN,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,,0.0025,,,10.1021/jm00106a048,
SD_409,YAAPKISLLAABEK-ROUUACIJSA-N,1,"(2S,3S)-5,8-dimethoxy-3-(phenethylamino)-1,2,3,4-tetrahydronaphthalen-2-ol",COC1=C2C(C[C@H](NCCC3=CC=CC=C3)[C@@H](O)C2)=C(OC)C=C1,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,21,,,10.1021/jm00387a008,
SD_410,PURLUGHPESZSPL-HLRBRJAUSA-N,2,"(2S,3S)-5,8-dimethoxy-3-((3-phenylpropyl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCC3=CC=CC=C3.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,5.5,,,10.1021/jm00387a008,
SD_411,OJYNMTOQYHTSDW-FKLPMGAJSA-N,3,"(2S,3S)-5,8-dimethoxy-3-((4-phenylbutyl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCCC3=CC=CC=C3.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,3.6,,,10.1021/jm00387a008,
SD_412,KVAVCBCHSXWXDA-GUTACTQSSA-N,4,"(2S,3S)-3-((3-(1H-indol-3-yl)propyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCC3=CNC4=C3C=CC=C4.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,23,,,10.1021/jm00387a008,
SD_413,CTEICORIZQCHMV-APTPAJQOSA-N,5,"(2S,3S)-3-((3-(benzo[d]thiazol-2-yl)propyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCC3=NC4=CC=CC=C4S3.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,13.5,,,10.1021/jm00387a008,
SD_414,PDRHRBGJGIOAJG-UKOKCHKQSA-N,6,"(2S,3S)-3-((2,2-diphenylethyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCC(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,13.3,,,10.1021/jm00387a008,
SD_415,FMBCOIIKBCPCFX-DKIIUIKKSA-N,7,"(2S,3S)-3-((3,3-diphenylpropyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCC(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,1.5,,,10.1021/jm00387a008,
SD_416,XAOSKPDNUZYJKQ-VDZUMBPESA-N,8,"(2S,3S)-3-((4,4-diphenylbutyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCC(C3=CC=CC=C3)C(/C=C)=C/C.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,0.8,,,10.1021/jm00387a008,
SD_417,MEHGKBPEHRVCRH-WMXJXTQLSA-N,9,"(2S,3S)-3-((5,5-diphenylpentyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCCCC(C3=CC=CC=C3)C4=CC=CC=C4.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,2,,,10.1021/jm00387a008,
SD_418,ZKXNBWBDVVMICH-DKIIUIKKSA-N,10,"(2S,3S)-3-((3,3-dicyclohexylpropyl)amino)-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-ol hydrochloride",O[C@H]1CC2=C(C(OC)=CC=C2OC)C[C@@H]1NCCC(C3CCCCC3)C4CCCCC4.Cl,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,,,,10.1021/jm00387a008,
SD_419,SGTNSNPWRIOYBX-UHFFFAOYSA-N,Verapamil,"5-((3,4-dimethoxyphenethyl)(methyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile",N#CC(CCCN(C)CCC1=CC(OC)=C(OC)C=C1)(C2=CC(OC)=C(OC)C=C2)C(C)C,,Pubchem,,In vitro calcium channel blocking assays,Yes,Reduction in blood pressure,Ca2+ channel,Spontaneously Hypertensive Rats,0.3,,,10.1021/jm00387a008,
SD_420,WQKSTZXYHFYAKY-UHFFFAOYSA-N,6a,"4'-((6-(benzylcarbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCC5=CC=CC=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0525,,,10.1016/j.ejmech.2012.01.009,
SD_421,NKVLENIRXUJTOR-UHFFFAOYSA-N,6b,"4'-((6-((2-methoxybenzyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCC5=CC=CC=C5OC,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0024,,,10.1016/j.ejmech.2012.01.009,
SD_422,PKDGXLSODONGNA-UHFFFAOYSA-N,6c,"4'-((6-((3-methoxybenzyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCC5=CC=CC(OC)=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.326,,,10.1016/j.ejmech.2012.01.009,
SD_423,LMZZNBSYLVXJQQ-UHFFFAOYSA-N,6d,"4'-((6-((4-methoxybenzyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCC5=CC=C(OC)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0043,,,10.1016/j.ejmech.2012.01.009,
SD_424,STQJLCIXSTXFST-UHFFFAOYSA-N,6e,"4'-((6-((3,4-dimethoxybenzyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCC5=CC=C(OC)C(OC)=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0306,,,10.1016/j.ejmech.2012.01.009,
SD_425,NCAWYFSYLMNGPT-UHFFFAOYSA-N,6f,"4'-((6-((3-methoxyphenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC=CC(OC)=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0308,,,10.1016/j.ejmech.2012.01.009,
SD_426,RIZLSQIVYHEYRR-UHFFFAOYSA-N,6g,"4'-((6-((4-methoxyphenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC=C(OC)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.214,,,10.1016/j.ejmech.2012.01.009,
SD_427,WMGJGWKGRCCRQX-UHFFFAOYSA-N,6h,"4'-((6-((3,4-dimethoxyphenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC=C(OC)C(OC)=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0576,,,10.1016/j.ejmech.2012.01.009,
SD_428,VOOYDDCVNCKBLQ-UHFFFAOYSA-N,6i,"4'-((6-((2,5-dimethoxyphenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC(OC)=CC=C5OC,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0013,,,10.1016/j.ejmech.2012.01.009,
SD_429,UEBSEYNILIIMEL-UHFFFAOYSA-N,6j,"4'-((6-((2-fluorophenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC=CC=C5F,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.106,,,10.1016/j.ejmech.2012.01.009,
SD_430,SGICQOPXUHBZIZ-UHFFFAOYSA-N,6k,"4'-((6-((4-fluorophenethyl)carbamoyl)-4-methyl-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC(C)=C2C(N(CC3=CC=C(C4=CC=CC=C4C(O)=O)C=C3)C(CCC)=N2)=C1)NCCC5=CC=C(F)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.198,,,10.1016/j.ejmech.2012.01.009,
SD_431,PSIFNNKUMBGKDQ-UHFFFAOYSA-N,losartan ,"(1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol",OCC1=C(N=C(N1CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)CCCC)Cl,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0162,,,10.1016/j.ejmech.2012.01.009,
SD_432,RMMXLENWKUUMAY-UHFFFAOYSA-N,Telmisartan,"4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",CC1=CC(C2=NC3=CC=CC=C3N2C)=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.001,,,10.1016/j.ejmech.2012.01.009,
SD_433,RMMXLENWKUUMAY-UHFFFAOYSA-N,Telmisartan,"4'-((1,7'-dimethyl-2'-propyl-1H,3'H-[2,5'-bibenzo[d]imidazol]-3'-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",CC1=CC(C2=NC3=CC=CC=C3N2C)=CC4=C1N=C(CCC)N4CC5=CC=C(C6=CC=CC=C6C(O)=O)C=C5,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.00049,,,h10.1021/jm200409s,
SD_434,PACFDFGGIPMOKL-QFIPXVFZSA-N,2a,"(S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CCC1=NC2=C(C)C=C(C)N=C2N1[C@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0076,,,h10.1021/jm200409s,
SD_435,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-cyclopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",2b(R+S),"(S)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CCC1=NC2=C(C)C=C(C)N=C2N1[C@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.096,,,h10.1021/jm200409s,
SD_436,PACFDFGGIPMOKL-JOCHJYFZSA-N,2c,"(R)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CCC1=NC2=C(C)C=C(C)N=C2N1[C@@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.661,,,h10.1021/jm200409s,
SD_437,UVDVRIXPMWDFIT-QHCPKHFHSA-N,2d,"(S)-3-(5-(2-(1H-Tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-5,7-dimethyl-2-propyl-3H-imidazo[4,5-b]pyridine",CCCC1=NC2=C(C)C=C(C)N=C2N1[C@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0133,,,h10.1021/jm200409s,
SD_438,HBYVOFWUGXPDMO-XMMPIXPASA-N,2e(R+S),"(R)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-butyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N([C@@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CCCC)=N2)=NC(C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.238,,,h10.1021/jm200409s,
SD_439,HIAQXCKTDNPVSH-HSZRJFAPSA-N,2f,"(R)-3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-isopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N([C@@H]3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(C(C)C)=N2)=NC(C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0102,,,h10.1021/jm200409s,
SD_440,KVHCBGFGXVLDGD-UHFFFAOYSA-N,2g,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-cyclopropyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(C7CC7)=N2)=NC(C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0082,,,h10.1021/jm200409s,
SD_441,PQLMUUHTNDBXNG-UHFFFAOYSA-N,2h,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5,6,7-trimethyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=NC(C)=C1C,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.202,,,h10.1021/jm200409s,
SD_442,BOHFIMKUULPBBT-UHFFFAOYSA-N,2i,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2,6-diethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=NC(C)=C1CC,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0157,,,h10.1021/jm200409s,
SD_443,XXWXOZMPDDSSEJ-UHFFFAOYSA-N,2j,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2,5-diethyl-7-methyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=NC(CC)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0068,,,h10.1021/jm200409s,
SD_444,BYKYONJSKPPTTO-UHFFFAOYSA-N,2k,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-5-ethyl-2-isopropyl-7-methyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(C(C)C)=N2)=NC(CC)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0169,,,h10.1021/jm200409s,
SD_445,HHFWRZYDWOGTJX-UHFFFAOYSA-N,2l,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=NC(CC(C)C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0016,,,h10.1021/jm200409s,
SD_446,HHBRJKDGDMTATE-UHFFFAOYSA-N,2m,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-5-isobutyl-2-isopropyl-7-methyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(C(C)C)=N2)=NC(CC(C)C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0035,,,h10.1021/jm200409s,
SD_447,AEXHTGISYTXJPO-UHFFFAOYSA-N,2n,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-7-isobutyl-5-methyl-3H-imidazo[4,5-b]pyridine",CC1=CC(CC(C)C)=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=N1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.748,,,h10.1021/jm200409s,
SD_448,VNCRGDCFGIGDGA-UHFFFAOYSA-N,2o,"3-(5-(2-(1H-tetrazol-5-yl)phenyl)-2,3-dihydro-1H-inden-1-yl)-5-benzyl-2-ethyl-7-methyl-3H-imidazo[4,5-b]pyridine",CC1=C2C(N(C3CCC4=C3C=CC(C5=CC=CC=C5C6=NN=NN6)=C4)C(CC)=N2)=NC(CC7=CC=CC=C7)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0052,,,h10.1021/jm200409s,
SD_449,PSGXDVSUDNDHBN-RUZDIDTESA-N,14,"(R)-2-(1-(2-ethyl-5-isobutyl-7-methyl-3H-imidazo[4,5-b]pyridin-3-yl)-2,3-dihydro-1H-inden-5-yl)benzoic acid",O=C(O)C1=CC=CC=C1C2=CC3=C([C@H](N4C(CC)=NC5=C(C)C=C(CC(C)C)N=C54)CC3)C=C2,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0105,,,h10.1021/jm200409s,
SD_450,YFWXFHNZGKNDBC-UHFFFAOYSA-N,15,"3-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridine",CC1=NC2=C(N=C(CC)N2CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3)C(C)=C1,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,,0.0027,,,h10.1021/jm200409s,
SD_451,MZEZWAFSRHXIMS-UHFFFAOYSA-N,6a, 4'-[(6-n-Propylaminocarbonyl-4-methyl-2-n-propyl-1H-benzimidazol-1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCC)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,1.345,,,10.1016/j.ejmech.2013.08.014,
SD_452,ILYZQINMZKUAIE-UHFFFAOYSA-N,6b, 4'-[(6-n-Butylaminocarbonyl-4-methyl-2-n-propyl-1H-benzimidazol-1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCCC)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.013,,,10.1016/j.ejmech.2013.08.014,
SD_453,MPPHJTGDWROIOP-UHFFFAOYSA-N,6c,"4'-((4-methyl-6-(morpholinocarbamoyl)-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NN5CCOCC5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,1.008,,,10.1016/j.ejmech.2013.08.014,
SD_454,RDMYIZJSQUDLBW-UHFFFAOYSA-N,6d, 4'-[[6-(1-Piperidinyl)carbonyl-4-methyl-2-n-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(N5CCCCC5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.02,,,10.1016/j.ejmech.2013.08.014,
SD_455,BZHLUYSOYJBCMN-UHFFFAOYSA-N,6e,4'-[[6-(4-methylphenyl)aminocarbonyl-4-methyl-2-n-propyl-1h-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NC5=CC=C(C)C=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.039,,,10.1016/j.ejmech.2013.08.014,
SD_456,RLIIGJWNLLPVGV-UHFFFAOYSA-N,6f, 4'-[[6-(2-phenylethyl)aminocarbonyl-4-methyl-2-n-propyl1h-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCC5=CC=CC=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.003,,,10.1016/j.ejmech.2013.08.014,
SD_457,KMSJMALTKMNVCA-UHFFFAOYSA-N,6g,4'-[[6-[2-(4-Morpholinyl)ethyl]aminocarbonyl-4-methyl-2-n-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCN5CCOCC5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.011,,,10.1016/j.ejmech.2013.08.014,
SD_458,ORALIHVHMAFAHT-UHFFFAOYSA-N,6h,4'-[[6-(3-phenylpropyl)aminocarbonyl-4-methyl-2-n-propyl1h-benzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCCC5=CC=CC=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.115,,,10.1016/j.ejmech.2013.08.014,
SD_459,SGTORJCNPYSWIC-UHFFFAOYSA-N,6i,"4'-((4-methyl-6-((3-morpholinopropyl)carbamoyl)-2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid",O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(C(NCCCN5CCOCC5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.01,,,10.1016/j.ejmech.2013.08.014,
SD_460,GTIKATHHODGEGX-UHFFFAOYSA-N,11a,4'-[(6-Acetylamino-4-methyl-2-n-propyl-1H-benzimidazol1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0003,,,10.1016/j.ejmech.2013.08.014,
SD_461,GEUPXOVRFJSXDQ-UHFFFAOYSA-N,11b,4'-[(6-n-Propionylamino-4-methyl-2-n-propyl-1H-benzimidazol-1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(CC)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0039,,,10.1016/j.ejmech.2013.08.014,
SD_462,DGXVMSJCVAIYLV-UHFFFAOYSA-N,11c,4'-[(6-n-Butyrylamino-4-methyl-2-n-propyl-1H-benzimidazol-1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(CCC)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0049,,,10.1016/j.ejmech.2013.08.014,
SD_463,GJJWDDROTHWGIF-UHFFFAOYSA-N,11d,4'-[(6-Benzoylamino-4-methyl-2-n-propyl-1H-benzimidazol1-yl)methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C5=CC=CC=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0012,,,10.1016/j.ejmech.2013.08.014,
SD_464,YDMPQPKAXQRBIE-UHFFFAOYSA-N,11e,4'-[[6-(4-Methylbenzoyl)amino-4-methyl-2-n-propyl-1Hbenzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C5=CC=C(C)C=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0001,,,10.1016/j.ejmech.2013.08.014,
SD_465,YDMPQPKAXQRBIE-UHFFFAOYSA-N,11f,4'-[[6-(4-Methylbenzoyl)amino-4-methyl-2-n-propyl-1Hbenzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(C5=CC=C(C)C=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0007,,,10.1016/j.ejmech.2013.08.014,
SD_466,PWVCJTQDCHXRDQ-UHFFFAOYSA-N,11g, 4'-[[6-(3-Phenylpropionyl)amino-4-methyl-2-n-propyl-1Hbenzimidazol-1-yl]methyl]biphenyl-2-carboxylic acid,O=C(C1=CC=CC=C1C2=CC=C(CN3C4=CC(NC(CCC5=CC=CC=C5)=O)=CC(C)=C4N=C3CCC)C=C2)O,,,,In Vitro AT₁  Receptor Binding Affinity,No,,AT₁  receptor,spontaneous hypertensive rats,0.0162,,,10.1016/j.ejmech.2013.08.014,
SD_467,LSNPOGOZVAHETR-UHFFFAOYSA-N,13,2-methoxy-4-(5-nitro-1H-benzo[d]imidazol-2-yl)phenol,OC1=CC=C(C2=NC3=CC([N+]([O-])=O)=CC=C3N2)C=C1OC,,,,Ex vivo vascular reactivity functional assay.,,,,spontaneous hypertensive rats,,1.81 ± 0.08,,10.1016/j.bmc.2010.04.027,
